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Although the antimicrobial potential of nitric oxide (NO) is 
widely published, it is little used clinically. NO is a key signalling 
molecule modulating vascular, neuronal, inflammatory and immune 
responses. Endogenous antimicrobial activity is largely mediated by 
high local NO concentrations produced by cellular inducible nitric 
oxide synthase, and by derivative reactive nitrogen oxide species 
including peroxynitrite and S-nitrosothiols. NO may be taken as 
dietary substrate (inorganic nitrate, L-arginine), and therapeutically as 
gaseous NO, and transdermal, sublingual, oral, intranasal and 
intravenous nitrite or nitrate. Numerous preclinical studies have 
demonstrated that NO has generic static and cidal activities against 
viruses (including β-coronaviruses such as SARS-CoV-2), bacteria, 
protozoa and fungi/yeasts in vitro. Therapeutic effects have been seen 
in animal models in vivo, and phase II trials have demonstrated that 
NO donors can reduce microbial infection. Nevertheless, excess NO, 
as occurs in septic shock, is associated with increased morbidity and 
mortality. In view of the dose-dependent positive and negative effects 
of NO, safety and efficacy trials of NO and its donors are needed for 
assessing their role in the prevention and treatment of infections. 
Trials should test dietary inorganic nitrate for pre- or post-
exposure prophylaxis and gaseous NO or oral, topical or intravenous 
nitrite and nitrate for treatment of mild-to-severe infections, including 
due to SARS-CoV-2 (COVID-19). This review summarises the evidence 
base from in vitro, in vivo and early phase clinical studies of NO activity 
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Introduction
Nitric oxide (NO), an inorganicmolecule, is generated endogenously by prokaryotes and eukaryotes fromL-arginine by a
family of NO synthase enzymes (NOS; Table 1.1).1 In higher animals, it is also generated by reduction of dietary and
endogenous nitrate (NO3
) to nitrite (NO2
) and thenceNO (Table 1.2). NO is a pleiotropic signallingmolecule involved
in vascular, neuronal and metabolic regulation and has multiple physiological effects including lowering blood pressure,
increasing exercise performance, and reversingmetabolic syndrome.Underlying these processes, NOmodulatesmultiple
cell types including leucocytes,2 platelets,3 endothelial cells and smooth muscle cells, and neuronal, cardiac and renal
function. Three isoforms of NOS exist in eukaryotes: neuronal (nNOS, NOS1), inducible (iNOS, NOS2) and endothelial
(eNOS,NOS3). Inmulticellular organisms,NOS1-3 producesNO that broadlymediates neurotransmission, cyto-toxicity
and vascular regulation respectively. Within cells, NO interacts with mitochondrial respiration, activates metabolic
regulatory pathways and reduces oxidative stress.
As people age, endothelial-derived vascular NO levels fall and so vascular function declines causing relative endothelial
dysfunction, pro-platelet and pro-inflammatory effects, and increased smooth muscle proliferation. Vascular NO levels
are even lower in people with established vascular disease, e.g. those with stroke.4,5 Numerous viruses (including adeno,
Coxsackie, coronavirus, cytomegalovirus, echovirus, herpes simplex, human T-cell leukaemia virus type-1, human
immunodeficiency virus, influenza, measles, mumps, polio) and bacteria (Leptospira spp.) can infect6–8 and damage
endothelium and so further reduce vascular NO levels. This also appears to occur in SARS-CoV-2 infection.9
Most physiological effects of NO are modulated by cyclic guanosine monophosphate (cGMP, second messenger),10,11
and terminated when cGMP is metabolised by phosphodiesterase-5 (PDE5). This combined L-arginine/nitrate-NO-
cGMP-PDE5 system (or nitric oxide system) comprises one of two key vasculo-protective pathways, the other being the
prostaglandin-cyclic adenosine monophosphate-phosphodiesterase-3 pathway (PG-cAMP-PDE3, or prostacyclin sys-
tem, see below).
The NO system may be enhanced or stimulated exogenously with substrate (L-arginine, organic nitrate, inorganic nitrite
or nitrate), NO gas, and PDE5 inhibitors. These can be inhaled or administered via transdermal, sublingual, oral, intranasal
or intravenous routes (see below). Since endogenous NO generated by inducible NOS plays a key role in defence against
multiple microbial pathogens (including viruses, bacteria, protozoa and fungi/yeast), this raises the possibility that
exogenous NO might have therapeutic potential as a broad-spectrum antimicrobial, and this is the topic of this review.
Methods for the review
There are numerous publications in this research area and our intention was not to perform a systematic review of these;
rather we present exemplars from the research field. We identified publications relating to the effect of NO on viruses,
bacteria, protozoa and fungi/yeasts from searches of our own reference libraries, PubMed and Google, and reference lists
given in earlier reviews and commentaries.12–20
The primary searches for relevant studies for inclusion were done through PubMed from inception to 4 May 2021,
in English with the following disease terms: “microbe” or “virus” or “bacteria” or “protozoa” or “fungi” or “yeast”.
The results of these searches were crossed with the drug terms “nitric oxide” or “nitrite” or “nitrate”, and the identified
abstracts were screened by one or more researchers. Earlier studies, including published reviews, were also identified
from the files of the senior author. Studies included in vitro, in vivo and clinical trials. Although other drug classes, such as
statins and angiotensin-converting enzyme inhibitors, enhance endothelial production of nitric oxide, their main effects
are mediated through other pathways, and we have not assessed them here even though they may attenuate microbial
disease severity.
Chemistry and biology of nitric oxide
NO is a small diatomic hydrophobic colourless gas that diffuses easily and has a short half-life. With an unpaired electron
(NO•), it is a free radical and so is chemically reactive and unstable in the presence of oxygen and superoxide producing
reactive nitrogen oxide species (RNOS). In reality, the chemistry of NO is more complex and it exists in several redox
forms: nitrosonium cation (NO+), NO (NO•) and nitroxyl anion NO).21
As an inorganic molecule, its central role in biology as a signalling molecule was only discovered in the 1980s,22 the
identification of which led to the Nobel Prize for Physiology andMedicine in 1998.23 Ironically, the medicinal use of NO
in the form of glyceryl trinitrate (GTN) for angina prophylaxis antedates the modern understanding of the biological
synthesis and role of NO by more than a century.24
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Experimental studies demonstrating nitric oxide inhibition of …
Viruses
Numerous preclinical in vitro studies have demonstrated that NO sources (stimulated endogenous NO, inorganic
and organic nitrates, L-arginine) and PDE5-inhibitors can reduce replication in all seven types of virus as defined
in the Baltimore classification (Table 2);25 this includes Class IV viruses (positive-sense RNA viruses) incorporating
several coronaviruses26–31 including SARS-CoV-2.32–34 Most studies showed efficacy although neutral studies were
reported for porcine reproductive and respiratory virus (an arterivirus, which is closely related to coronaviruses) and
rhinovirus.35,36
Bacteria
Multiple studies have assessed the effect of NO on bacteria and inhibitory effects have been seen across a wide range of
gram negative, gram positive and acid-fast bacteria (Table 3). NO sources included L-arginine, NO, nitrite, organic
nitrates, and endogenously-generated NO. Multiple mechanisms for efficacy have been reported, as discussed below.
Protozoa
NO sources have been tested on both intracellular and extracellular protozoa (Table 4) with sources involving activated
macrophages, sodium nitrite, glyceryl trinitrate, sodium nitroprusside (SNP) and S-nitroso-L-acetylpenicillamine
(SNAP).
Fungi and yeasts
The effects of NO on several fungi and yeasts have been studied (Table 5). NO was donated exogenously through
stimulating macrophages or as acidified nitrite. In vitro experiments demonstrated reduced replication whilst in vivo
experiments in mice showed reduced infection.
Derivatives of nitric oxide
Whilst endogenous NO derived from eNOS and nNOS is physiologically active via its second messenger (cGMP), the
antimicrobial effects of NO relate to its toxic effects when present at higher concentrations. Although it is technically
challenging to measure free NO concentrations, studies suggest that NO concentrations derived from iNOS are 10–100
higher than those resulting from eNOS/nNOS (Table 6). NO concentrations resulting from exogenous administration lie
between those from eNOS/nNOS and iNOS but approximate more closely to those from iNOS than eNOS. Importantly,
much antimicrobial NO activity is likely to reflect the effects of derivative molecules rather than NO itself:
Table 1. Chemical equations relevant to the nitric oxide system.
No. Substrate Product Enzyme Biochemical equation
1. L-arginine NO Nitric oxide
synthase
2 L-arginine + 3 NADPH + 3 H+ + 4 O2 à




 + e + 2 H+ à H2O + NO2

2 NO2
 + 2 H+ à 2 HNO2 à N2O3 + H2O
N2O3 à NO + NO2
3. NO Peroxynitrite NO• + O2
• à OONO
4. Superoxide Hydrogen peroxide Superoxide
dismutase
O2
 à O2 + H2O2
5. Nitrite Peroxynitrous acid NO2
 + H2O2 à ONOOH
6. NO Nitrogen dioxide 2 NO + O2 à 2 NO2; ONOOH à NO2 + OH





2 NO2 à N2O4
9. Hydrogen
peroxide
Hydroxyl radicals H2O2 à OH
 + OH• à DNA damage
10. NO Nitrous oxide NO reductase 2 NO + NAD(P) H + H+ à N2O + H2O +
NAD(P)+
11. NO Nitrate NO
dioxygenase
Fe3+(O2
) + NO à Fe3+ + NO3

Note: Many of these reactions can occur in the opposite direction, e.g. inhaled NO2, an environmental pollutant, is a source of bioactive
intravascular nitrite.187
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• Nitric oxide (NO•). In general, bacteria deficient in low molecular weight thiols such as glutathione (e.g.
Staphylococci spp.) are sensitive to attack byNOwhereas thosewith high thiol concentrations are resistant toNO.
• Peroxynitrite (OONO-, Table 1.3). The reaction between NO and superoxide means that NO synergises with the
respiratory burst, another antimicrobial system present in phagocytic cells. Experimentally, this synergism can be
inhibited with the addition of superoxide dismutase which converts superoxide into molecular oxygen and
hydrogen peroxide (Table 1.4).
• Peroxynitrous acid (ONOOH, Table 1.5), e.g. toxic to Escherichia coli.37
• Nitrogen dioxide (NO2, Table 1.6), e.g. toxic to E. coli.
37
• Dinitrogen trioxide (N2O3, Table 1.7).
• Dinitrogen tetroxide (N2O4, Table 1.8).
• S-nitrosothiols (RSNO, e.g. S-nitrosoglutathione), e.g. toxic to E. coli and Salmonella enterica serovar typhi-
murium.38 RSNO reacts with protein sulphydryl groups changing their function. Thiol concentrations do not
appear to determine sensitivity to peroxynitrite and S-nitrosothiols.
• Dinitrosyl-iron ((2 RS)-Fe-(2 NO)). The reaction of NO with iron or iron–sulphur molecules can: inactivate
enzymes such as aconitase (which converts citrate to isocitrate in the citric acid cycle), ribonucleotide reductase
and ubiquinone reductase; increase free ferrous (Fe2+) which causes oxidative damage; and deplete iron stores.
• RNOS (especially auto-oxidised products of NO).
Since these molecules differ in their stability, reactivity, location and cellular diffusivity, the overall effect of NO will
depend on the molecular species involved and its location.
Cellular and other targets of nitric oxide
The targets for NO and associated reactive nitrogen species are multitudinous:
• DNA, through deamination of adenine, cytosine and guanine;39 cross-linking; breakage of strands; inhibition of
DNA repair enzymes such as DNA alkyl transferases (and so preventing transfer of the guanine alkyl group to
Table 6.Nitric oxide concentrations followingendogenous synthesis bynitric oxide synthase, and exogenous
NO donors.
NO eNOS/nNOS iNOS Exogenous
NO
Source Endothelium, neurones Intracellular, e.g. macrophages Exogenous






Inducible, continuous (“fire hose”17),
calcium-independent/cytokine-microbial
dependent. Part of innate immunity
Concentration 0.1-5 nM240 >10 μM240 SNP, 52
nM241





Effects Reversible Irreversible. Nitrosation, nitration,
oxidation.
Reversible
CcOX: cytochrome c oxidase (Complex IV); sGC: soluble guanylate cyclase; SNP: sodium nitroprusside.
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protein); and disruption of DNA replication by inhibition of ribonucleotide reductase;40 as in S. enterica and
vaccinia virus.
• RNA, through disruption of RNA replication by inhibition of viral ribonucleotide reductase.
• Inhibition of mitochondrial function, specifically through inactivation of iron-sulphur complexes within respi-
ratory chain enzymes.41
• Protein modification at cysteine, methionine, phenylalanine, tryptophan and tyrosine residues, e.g. by RNOS.
Such protein effects will reduce enzyme activity, as seen for DNA, proteases42 and mitochondrial function, as in
Coxsackievirus.42
• Limit late protein synthesis, e.g. through posttranslational modification of viral proteases. (Early protein
translation/synthesis is not typically affected.)
• Induction of lipid peroxidation.
• Limit glutaminolysis by shuttling glutamine to glutathione synthesis, as in cytomegalovirus.43
• Interaction with sulfhydryl-containing constituents of the bacterial cell.44
• Disrupt zinc homeostasis, as in S. enterica.45
• Limit virion assembly/particle formation.
• Reduce bacterial adhesion to NO-releasing surfaces.46
Nitric oxide may also play an augmenting role as an antimicrobial agent. Examples include the adjuvant roles of NO
when given with type I interferons in the treatment of DNA viruses47 and L-arginine when given with conventional
chemotherapy in smear-positive TB.48
In addition, NO’s vasculo-active effects are likely to be beneficial in preventing infection and its severity, with NO:
• Reversing endothelial dysfunction and so potentially reducing endotheliitis,9 as occurs in COVID-19.7,8
• Reducing leucocyte function (e.g. adhesion, chemotaxis, phagocytosis);2 COVID-19 is associatedwith increased
phagocyte counts.8,49
• Reducing platelet activation and platelet–leucocyte conjugation and so reducing micro- and macro-thrombosis,
as seen in COVID-19.8,50
• Improving organ blood flow and perfusion through smooth muscle relaxation and vasodilation and so likely
reversing infection-related vasoconstriction as seen in COVID-19,8 including in the pulmonary circulation.51
These actions of NO are all mediated via the second messenger cGMP.
Antimicrobial production of nitric oxide
NO is produced by some bacteria, archaea and yeasts via several pathways including denitrification of nitrate to nitrite and
then to NO52 and oxidation of L-arginine to NO and L-citrulline as catalysed by a bacterial nitric oxide synthase (bNOS),
a process that can be inhibited by NOS inhibitors.53 Whilst eukaryotic NOS contains both catalytic and reductase
domains, prokaryotic bNOS lacks the latter relying instead on other cellular reductases to generate NO; the one exception
to this is the bNOS present in Sorangium cellulosum which does include a reductase module.
In contrast to the signalling role of NO in mammals, NO synthesis in bacteria has multiple functions which vary between
antimicrobial species:54–57
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• Protection against oxidative stress with NO limiting thiol reduction and so the formation of hydroxyl radicals
(Bacillus anthracis/subtilis, Staphylococcus aureus54) (Table 1.9).
• Protection against oxidative stress with NO activating catalase (B. subtilis). Such defence will limit damage from
phagocytic respiratory bursts.54
• Protection against oxidative stress by reducing endogenous NO synthesis and increasing the expression of NO
dioxygenase to detoxify NO (Candida albicans).56
• Biosynthesis of toxins, e.g. thaxtomins (a phytotoxin) interfere with potato plant wall synthesis (Streptomyces
turgidiscabies).54
• Activation of aerobic and nitrate respiration to optimise growth (S. aureus).57,58
• Protection against antimicrobial agents including amoxycillin, cefuroxime, gentamicin and novobiocin
(B. anthracis/cereus/thuringiensis/weihenstephanensis, S. aureus),55 and azoles (Candida albicans).56
The production by somemicrobes of endogenous NO to protect against oxidative stress is ironic since hosts are using NO
to try to destroy the microbe!
Resistance to nitric oxide
Microbial resistance to antibiotics is an increasingly common problem and has left some bacteria with few treatment
options, e.g. drug-resistant Neisseria gonorrhoeae. Hence, it is vital to consider whether resistance to NO is innate in
some microbes or can be acquired. As already highlighted, some microbes have an intrinsic ability to produce their own
NO and so attenuate the effects of oxidative stress (e.g. B. anthracis/subtilis, C. albicans, S. aureus 54,56), activate aerobic
respiration (S. aureus57) or protect against antimicrobial agents (B. anthracis/cereus/thuringiensis/weihenstephanensis,
C. albicans, S. aureus 55,56).
Microbes may also have mechanisms for deactivating NO. One mechanism is via a NO reductase which reduces NO to
nitrous oxide and then nitrogen, e.g. as occurs in fungi59 (Table 1.10). Bacteria have different NO reductases but similarly
produce nitrous oxide,59 as seen in Pseudomonas aeruginosa.52 Loss-of-function mutations in NO reductase may be
lethal, possibly because intracellular NO concentrations rise to toxic levels.
A second mechanism for detoxifying NO is via NO dioxygenase oxidation to nitrate (Table 1.11). The pre-eminent NO
dioxygenase is flavohaemoglobin,60 as present in bacteria (e.g. Salmonella enterica, S. aureus, Vibrio cholerae, Yersinia
pestis,20,61,62) and yeasts. A related haemoglobin, truncated haemoglobin, detoxifies NO in mycobacteria. Of note,
Mycobacterium leprae has undergone reductive genome evolution losing more than 2,000 genes, including some that
protect against RNOS; as a result,M. leprae has fewer defences against NO thanMycobacterium tuberculosis.63 Bacterial
lactate dehydrogenase also detoxifies NO, as seen in S. aureus.20 Importantly, these detoxifying enzymes only cope with
low levels of NO and are not protective against high NO levels.
As a result, microbes show differing sensitivities to NO, as seen for common airways pathogens where sensitivity was
ranked (sensitivity most to least): P. aeruginosa ~ C. albicans > S. aureus > Klebsiella pneumoniae ~ Staphylococcus
epidermis.64
However, there is little evidence that bacteria can acquire de novo resistance to NO, as confirmed in experiments on
strains of E. coli, P. aeruginosa, S. aureus and Staphylococcus epidermidis.65 This property is unsurprising since NO has
multiple mechanisms for antimicrobial activity and these are likely to be invoked orders of magnitude faster than any
microbe can process metabolically, especially if protein synthesis is required. Equally, the main mechanisms for
antibiotic resistance (drug inactivation, altered binding sites or metabolism and reduced drug permeability) are unlikely
to be relevant to many NO sources. Whether viruses, protozoa and fungi can develop resistance to NO remains unclear.
Administering nitric oxide, donors and related compounds
L-arginine
In the presence of NOS, administration of L-arginine may enhance NO synthesis (Table 7) although intracellular
L-arginine levels are not normally rate limiting and so administrationmay not have physiological effects.66 Although oral
Page 14 of 34






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 15 of 34



















































































































































































































































































































































































































































































































































































































































































































































































































































Page 16 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
preparations of L-arginine are commercially available, consumption of high doses is associated with profuse diarrhoea
(P Bath, personal observation).
Inhaled nitric oxide
Gaseous NOmay be inhaled with the aim of improving pulmonary haemodynamics and killing microbes. Multiple trials
are underway for COVID-19 prevention and treatment (Table 9). NO may also be created in real time by combining
sodium nitrite and citric acid and administering this either as a nasal spray (for local therapy) or via nebuliser (for
combined nasal and bronchial therapy).
Organic nitrates
Organic nitrates such as GTN, isosorbide dinitrate (ISDN) and isosorbidemononitrate (ISMN) are widely used in vascular
medicine for the prevention and treatment of angina, treatment of chest pain in unstable angina and myocardial infarction,
treatment of severe heart failure, and blood pressure lowering after cardiac surgery and in acute stroke (Table 7). There
is increasing concern that chronic use of organic nitrates may cause major adverse cardiac events and death,67 reduce
daily activity,68 and not improve quality of life or exercise capacity.68 Potential explanations include the development
of tolerance, and induction of endothelial dysfunction and cell damage through oxidative stress, e.g. production of free
radicals/peroxynitrite.69,70
Importantly, organic nitrates only release NO in cells and tissues expressing mitochondrial aldehyde dehydrogenase-2.71
For example, SNP and SIN-1 inhibit monocyte chemotaxis whilst organic nitrates (ISDN, GTN and molsidomine) do
not;72 this contrasts with smooth muscle cells which vasodilate with all five agents. Since aldehyde dehydrogenase-2
suffers from use-inactivation, nitrate tolerance (tachyphylaxis) and endothelial dysfunction develops70 and bioconver-
sion only restarts following a nitrate-free period. Several in vitro studies have demonstrated the potential antimicrobial
effects of organic nitrates (Table 7). Other non-organic nitrates include pentaerythritol tetranitrate and erythrityl
tetranitrate.
Therapeutic inorganic nitrite and nitrate
Therapeutic use of inorganic nitrite is limitedwith intravenous administration used in cyanide poisoning (British National
Formulary). Topical acidified sodium nitrite has been shown to reduce cutaneous infections secondary to a variety of
viruses and bacteria although its general use is probably limited by skin irritation and erythema (Table 7).
Dietary inorganic nitrate
NOmay also be produced from dietary inorganic nitrate, as is present in high concentrations in green leafy and some root
vegetables, e.g. spinach, lettuce, rocket, beetroot, celery, fennel, radish and Chinese cabbage.73 Nitrate is absorbed from
the proximal gastrointestinal tract, excreted by salivary glands, reduced to nitrite by oral bacteria and then absorbed in the
gastrointestinal tract. A number of bacterial species situated on the dorsal surface of the tongue perform this conversion
via nitrate reductases.74 (In the absence of oxygen, nitrate and nitrite are commonly used by bacteria as terminal electron
acceptors for respiration.75) Through this symbiotic relationship, the mammalian host provides the nutrients and the
environment in return for nitrite production by bacteria.76
Absorbed and circulating nitrite is then further reduced to NO, a process that is enhanced in hypoxic or acidic conditions
and by multiple mechanisms including deoxyhaemoglobin, deoxymyoglobin, xanthine oxidoreductase and endothelial
nitric oxide synthase.77,78 As such, most effects of dietary nitrate will be vascular and perivascular. The beneficial
vascular protective effects of vegetable consumption are very clear epidemiologically, as present in the classical Japanese
diet,79 the Dietary Approaches to Stop Hypertension (DASH) diet,80 and theMediterranean diet.81,82 Further, vegetable-
derived nitrate may reduce the risk of gastrointestinal cancer.73,83,84 The benefit on cancer is at variance with oral
consumption of nitrite. Although nitrite is not carcinogenic per se, the processing and cooking of nitrite-cured meat can
form carcinogens such as N-nitroso compounds and heterocyclic aromatic amines. In contrast, carcinogens are not
formed when eating raw vegetable-derived nitrate. A recent meta-analysis showed an increased risk gastric cancer with
oral nitrite but reduced risk with oral nitrate.85 Dietary nitrate is known to modify the oral and gastric biome (Table 7).
High dietary intake of nitrate is associated with many mechanisms that may have beneficial vascular, and potentially,
antimicrobial effects. Experimentally, beetroot juice is often used as a potent source of dietary nitrate since dosing can be
controlled and a nitrate-free placebo version is available for use in randomised controlled trials. Studies have shown that
beetroot juice increases plasma nitrate and nitrite concentrations,86,87 that most vascular effects are mediated via the
secondmessenger cGMP,87 tolerance does not develop (unlike with organic nitrates)73 and inorganic nitrate does not lead
to free radical formation. In clinical studies, beetroot juice has been given over weeks and months86–91 and has been
shown to have multiple effects with improved exercise performance (hence use by elite athletes)92; improved cognitive
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performance in older people92; vasodilation with reduced blood pressure89,90,92–95; antiplatelet and anti-leucocyte effects
and reduced platelet-leucocyte conjugation86,89; improved endothelial function; reduced left ventricular volume;91
improved metabolic profile; and improved oral health.89 Beyond anti-inflammatory effects on blood cells, nitrite or
nitrate reduce soluble pro-inflammatory factors including C-reactive protein, chemokine (C-X-C motif) ligand-1/2,
endothelin-1, interleukins-1β/6/10/12p70, interferon-γ, monocyte chemoattractant protein and tissue necrosis factor-α.96
Dietary nitrate has profoundmetabolic effects and appears to have the potential for reversing themetabolic syndrome and
have anti-diabetic effects.97Overall, the pharmacological effects of beetroot juice have been demonstrated in younger and
older people, and in people with cardiovascular disease, e.g. diabetes, obesity, hypertension, hypercholesterolaemia,
heart failure and stroke.98 Importantly, inorganic nitrate (given as beetroot juice) may be taken by pregnant women.99
Experimentally, watermelon juice and chard gel may be used as an alternative source of dietary nitrate.100,101
Phosphodiesterase-5 inhibitors
PDE5-inhibitors, such as dipyridamole and sildenafil, enhance the physiological effects of NO as mediated by cGMP.
Whether these agents should have antimicrobial effects is unclear since they do not enhance NO levels per se;
nevertheless, both drugs have exhibited antimicrobial activity (Table 7) and are being tested in COVID-19 trials
(Table 9).102,103
Stimulation of endogenous nitric oxide-dependent nitric oxide production
EndogenousNOproductionmay also be stimulated externally. First, nasal breathing promotes the production ofNO from
the paranasal sinuses and this has bronchodilatory, vasodilatory and potential antimicrobial activities.104 This natural
defence mechanism may be attenuated with mouth breathing, as occurs with increasing age and obesity. Second,
ultraviolet radiation (UVA and UVB) stimulates the release of NO from both keratinocytes and melanocytes; NO has
multiple effects including attenuation of free radical damage, melanogenesis, blood pressure lowering105 and potentially
protection against skin infections.
Novel nitric oxide agents
Recent research has focussed on the development of new antimicrobial NO delivery systems and some examples are
listed:
• NO microspheres, e.g. biodegradable poly (lactic-co-glycolic acid) spheres loaded with S-nitroso-N-acetyl-D-
penicillamine.106
• NO-releasing nanoparticles, with activity against Acinetobacter baumanii, C. albicans, Enterococcus faecalis,
E. coli,K. pneumoniae, P. aeruginosa, S. aureus (MRSA), S. epidermidis, Trichophyton menatgrophytes.105,107
• Modified chitosan, e.g. against Trypanosoma cruzi,108 E. coli, S. aureus, Streptococcus mutans.109
• NO–metal complexes (zeolites), with activity against B. subtilis, Clostridium difficile, E. coli, P. aeruginosa,
S. aureus (including MRSA).105
• NONOoates (diazeniumdiolates), e.g. with activity against C. albicans, E. coli.105,110
• NO coating of medical device surfaces and tubing,111,112 e.g. using S-nitroso-N-acetyl-D-penicillamine to kill
Staphylococcus aureus and P. aeruginosa.
NO sources can also be categorised by whether administration is local (e.g. cutaneous nitrite or intranasal preparations),
systemic (e.g. dietary nitrate or L-arginine, oral isosorbide or sildenafil, sublingual GTN, intravenous GTN or SNP) or
mixed local and systemic (transdermal GTN). Local administration allows high and potentially cidal concentrations of
NO to be achievedwithout unwanted systemic effects. Intravenous formulationsmight allow for systemic infections to be
treated.
Relevance of in vitro studies to preclinical and clinical studies
Most microbial studies presented above and in Tables 2-5 were performed in vitro and involved either inducing the
L-arginine/NO pathway with cytokines (e.g. interferon gamma [IFN-γ] and/or lipopolysaccharide [LPS]) or with NO
sources (such as NO gas, nitrite, 3-morpholinosydnonimine, S-nitroso-L-acetylpenicillamine or sodium nitroprusside).
However, the inhibitory effect of NO on microbes in vitro does not represent the complex biochemical environment that
they face in vivo including the presence of NO derivatives such as peroxynitrite, microbial production of NO, microbial
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resistance toNO and excess NO synthesis. Nevertheless, there aremany ex vivo and clinical examples where NOhas been
effective. These issues are now discussed.
Nitric oxide for clinical infections
Oral health and gastrointestinal infections
As already highlighted, oral bacteria (e.g. Corynebacterium pseudodiphtheriticum,Fusobacterium nucleatum,Nocardia
spp., Prevotella melaninogenica, S. aureus, S. epidermidis, Veillonella spp.) are vital for the reduction of salivary nitrate
to nitrite as part of the entero-salivary circulation; nitrite is further reduced to NO.113 This represents a symbiotic
relationship between bacteria and the mammalian host; the host provides the nutrients and the environment in return for
nitrite production,76 as in the absence of oxygen, nitrate and nitrite are commonly used by such bacteria as terminal
electron acceptors for respiration.75
Oral consumption of nitrate and the resulting increase in nitrite in the oro-pharynx leads to salivary alkalinisation
(pH ~7.0 to 7.5)114 and so reduction in detrimental bacteria and caries.74 Similarly, nitrate supplementation was
associated with increased oral Rothia spp. and Neisseria spp, and diminished oral Prevotella spp. and Veillonella
spp.; in parallel, plasma nitrite levels rose and systemic blood pressure fell.115 Salivary nitrite production is related to the
abundance of oral-nitrate-reducing bacteria.116 In contrast, bacteria and yeast, in particular Lactobacillus spp., Strepto-
coccus spp. and C. albicans, are key to the development of dental caries through the production of acid. Equally,
antibiotics that kill nitrate-reductase-containing bacteria inhibit oral nitrite production and so increase the risk of oral
thrush.117 Acidified nitrite has antibacterial activity against Helicobacter pylori in vitro,118 an experiment that likely
mimics the scenario seen by these bacteria in the stomach after a nitrate/nitrite-rich meal.
Cutaneous infections
The skin is a potent source of nitric oxide and production is increased with exposure to sunlight (specifically ultraviolet
radiation) sufficient to lower blood pressure.119,120 Hence, skin-derived NO may form a natural dermatological
antimicrobial defence. Numerous studies have demonstrated that topical acidified sodium nitrite reduces cutaneous
infections due to a variety of viruses and bacteria (Table 7) although prophylaxis had to be continued in some cases since
NO suppressed replication without necessarily being viro-toxic.121–126 Inorganic nitrate has been used for the treatment
of human papilloma virus.127 Phase II clinical trials have found that acidified nitrite in cream reduced Leishmania major/
tropica amastigotes and promastigotes with a reduction in cutaneous leishmaniasis123 and increased cure rates in tinea
pedis.121 Novel NO agents are in development to treat skin conditions (Table 8).
Respiratory infections
In animal and human experiments, NO substrate (L-arginine) and a NO donor (SNP) has been shown to improve the
mucociliary activity of the upper respiratory tract128 suggesting a modulatory role for NO in nasal barrier function and
clearance. Novel NO agents building on this observation are in development (Table 8):
Endogenous NO has potent pulmonary haemodynamic and bronchodilator effects physiologically. The importance
of endogenous NO in preventing infection is apparent experimentally where inhibition of NO results in increased
susceptibility to microbes including Leishmania spp., Mycobacterium spp. and Plasmodium spp.129 Similarly, NO
sources are used therapeutically, for example sildenafil in the management of pulmonary hypertension (Table 7). In
respect of airway epithelial cells, nitrite reduced P. aeruginosa biofilm growth.130 In infection, NO reduces pulmonary
vascular resistance and intrapulmonary shunt, and improves oxygen partial pressure in patients with acute severe
pneumonia.131 More specifically, inhaled NO improves arterial oxygenation enabling a reduction in inspired oxygen
therapy and airway pressure support, and reduces lung infiltrates, in patients with severe acute respiratory syndrome
(SARS).31 These findings continue after termination of NO therapy suggesting that NO has both pulmonary vasodilator
and anti-SARS effects. Small uncontrolled clinical studies have suggested that iNO may be beneficial in COVID-
19.132–136 iNO and novel NO agents are in development, primarily for COVID-19 at present (Table 8, 9).
Dipyridamole, a phosphodiesterase 5 inhibitor, may also have similar beneficial effects in severe COVID-19.33 A
phase II clinical trial found that L-arginine might have beneficial effects when given on top of conventional therapy for
tuberculosis (Table 7).48
Urinary tract infections
There may also be a role for dietary nitrate/inorganic nitrite in the prevention and treatment of urinary tract infections.
Many of the lower urinary tract opportunistic organisms (e.g. E. coli) possess nitrate reductases, this forming the basis of
urine dipstick detection of nitrite. In acidic urine conditions, nitrite is reduced toNOwith toxicity to bacteria; for example,
transferring nitrite-rich urine containing E. coli to a more acidic environment (e.g. pH 5.5) dose-dependently inhibited
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bacterial growth,137 an effect potentiated by vitamin C. The antibacterial potency is comparable to conventional
antibiotics such as trimethoprim and nitrofurantoin.
This approach has been tested by filling urinary catheter retention balloons with nitrite and ascorbic acid, resulting in
measurable amounts ofNOoutside themembrane and effectively killing two strains ofE. coli in the surrounding urine.138
A similar approach found decreased bacterial counts and prevented biofilm formation by P. aeruginosa,K. pneumoniae,
and Enterobacter cloace (but not E. coli or S. aureus).139
Last, instillation of bacillus Calmette-Guerin (BCG, an attenuated strain ofMycobacterium bovis) into the bladder is used
for the treatment of superficial/non-muscle invasive bladder cancer and carcinoma in situ. BCG induces long-term
increases in NOS activity in urothelial cells140,141 and the formed NO is toxic to the malignant cells. The use of BCG to
provide non-specific protection against SARS-CoV-2 is to be tested142,143 although vaccination in infancy does not
appear to protect against COVID-19 in adults.144
Other infections
Nitrate (usually KNO3) and nitrite (NaNO2) have been used for millennia to preserve food, especially meat and fish.
145
Food preparation leads to reduction of nitrate to nitrite, and nitrite inhibits bacterial growth, especially Clostridium
Table 8. Examples of commercial development of novel nitric oxide donors/agents with efficacy against
target disease and microbes (where relevant, last searched 15 March 2021).
Target organism/disease Commercial
company
NO gas for inhalation Beyond Air
NO gas for inhalation INOmax
NO-releasing solution for nebulisation
(sodium nitrite and citric acid)
COVID-19 30 Technology
NO released from acidified nitrite via a
semi-permeable membrane
Cutaneous S. aureus, E. coli249
NO macromolecular scaffolds,46,250 e.g.
NO-releasing cyclodextrins251
P. aeruginosa Vast Therapeutics
Polymer-based chronic NO delivery
systems e.g. for treatment of biofilms,252
Cutaneous viruses (human papilloma
virus, molluscipoxvirus),
dermatophytes (Epidermophyton
floccosum, Fusarium solani, T. rubrum,





NO-releasing nasal spray (NORS1002)
NO-releasing nasal lavage (NORS4002)
Acne (Propionibacterium), fungal nail
infections/onychomycosis (T. rubrum,
T. interdigitale)





NO-stimulating nasal spray (GLS-1200) GeneOne Life Science




NO-generating probiotic patches, e.g.
based on Lactobacilli conversion of
glucose to lactic acid, and acidification of
sodium nitrite221,245
S. aureus McGill University,
Canada
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botulinum, a key and severe cause of neurotoxin poisoning. Additionally, nitrite adds colour to food,58,146 flavour (in part
by overcoming rancid tastes) and is an antioxidant.
NO donors have also been investigated for eradicating or dispersing biofilm organisms. For example, GTN synergises
with citrate and ethanol in eradicating biofilms (related to S. aureus, MRSE, P. aeruginosa and C. albicans) in an
experimental catheter lock model.147 Similarly, isosorbide mononitrate synergised with antibiotics to disperse then kill
S. aureus.148 An NO-releasing contact lens has been developed to treat microbial keratitis due to P. aeruginosa and
S. aureus).149
GTN may have improved outcome after infection in participants enrolled into the RIGHT-2 trial, a study where
paramedics recruited patients with suspected stroke and randomised them to GTN versus sham. Overall, the trial was
neutral.150 However, in a planned subgroup analysis of those participants with a final diagnosis of a non-stroke mimic,
functional outcome was better with GTN.150 In a post hoc analysis of participants in this subgroup, GTN was associated
with a better outcome in those with a final diagnosis of infections of the respiratory and urinary tracts which raises the
possibility that NO was treating the infectious cause underlying the stroke mimic diagnosis.
The prostaglandin-cyclic adenosine-phosphodiesterase-3 system
As with the NO system, the prostaglandin-cyclic adenosine monophosphate-phosphodiesterase-3 (PG-cAMP-PDE3)
system has similar vasculo-protective roles with anti-leucocyte, antiplatelet and anti-smooth muscle, and pro-endothelial
effects. It is therefore interesting to note that prostaglandins (PGA1, PGJ2), including prostacyclin (PGI2 and analogues),
have been reported to have antiviral effects.151–154 Whether drugs based on these155 or the PDE3 inhibitor, cilostazol,
have efficacy against SARS-CoV-2 remains to be investigated. Further, endogenous NO and PGI2 work together in the
vascular tree, and it is conceivable that their potential antimicrobial effects will similarly synergise. Their combination, in
the forms of ISMN and cilostazol, have been tested after stroke156 but not yet reported for the prevention or treatment of
infection.
Interaction between nitric oxide and vaccine efficacy
The interaction between diet, nutrition state and vaccine effectiveness has been assessed inmultiple studies, principally in
low–middle income countries where vaccination is paramount, especially in children, and yet where malnutrition may be
widespread. In a systematic review andmeta-analysis of observational studies and randomised controlled trials, there was
little suggestion that malnutrition had any effect on vaccine responses157; similarly, supplementation with vitamins
and D, and iron and zinc, did not appear to modify responses. In preclinical studies, protein-energy malnutrition had
limited influence on vaccine efficacy in mice.158 The effect of dietary nitrate levels on vaccine efficacy is unstudied.
If nitric oxide derivatives attenuatemicrobial infections, then the efficacy of vaccines based on live attenuated viruses and
bacteria (such as measles, poliovirus, BCG) might be attenuated by treatment with NO. Although there are many factors
known to alter vaccine effectiveness (e.g. age), the effect of NO has not been studied.
Post-infection morbidity
Many infections cause long-term morbidity with chronic fatigue syndrome (CFS) and symptoms including fatigue,
tiredness, myalgia, cognitive impairment and depression. Example associated microbes include Borrelia burgdorferi
(Lyme disease), Chlamydia pneumoniae (community acquired pneumonia), Epstein–Barr virus (infectious mononucle-
osis), human herpes virus 6 (exanthema subitem), human immunodeficiency virus (AIDS), polio virus, SARS-CoV-1
virus (SARS), SARS-CoV-2 (long-COVID) andWest Nile virus (fever).159–161 Although CFS may represent chronic or
latent infection, it is more likely to reflect the presence of post-infectious chronic inflammation. Hypothetically, these
patients might benefit from inorganic nitrates in view of their positive effects on exercise performance (elite athletes take
beetroot juice for this purpose) and cognition,73,92 and potentially antimicrobial effects, a question that needs addressing
(Table 7). A phase II trial of L-citrulline is studying this approach in patients with post-polio syndrome.162
Excess nitric oxide during infection
During severe infection, sepsis (defined as “life-threatening organ dysfunction caused by a dysregulated host response to
infection”) often develops. Septic shock is a subset of sepsis and is a leading cause of death worldwide.163 It manifests as
hyper- or hypo-pyrexia, altered mental state, hypotension, tachycardia, tachypnoea, hypoxia, anuria and/or lactataemia.
This can occur with many infections due to:
• Gram negative bacteria: Bacteroides fragilis, C. pneumoniae, Enterobacter spp., E. coli, Haemophilus influen-
zae, Klebsiella spp., Legionella spp., Neisseria meningitidis, Proteus spp., P. aeruginosa, Yersinia pestis.61
Page 22 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
• Gram positive bacteria: Clostridium spp., Enterococcus spp., Listeria monocytogenes, Staphylococcus spp.,
Streptococcus agalactiae/pneumoniae/pyogenes
• Viral: Adenovirus, Coronaviruses, Dengue viruses, Ebola virus, Enteroviruses, human immunodeficiency virus,
Influenza virus (A and B), haemorrhagic fever viruses, Parechoviruses.164,165
• Fungi: Candida spp.166
• Protozoa: Plasmodium falciparum, Schistosoma mansoni.167
Typically, autoamplification of circulating cytokines (so-called cytokine storm) leads to excess NO synthesis, mostly
derived from inducible NOS, leading to high circulating NO levels and the development of septic shock. In these
circumstances, treatment with exogenous NOmight be inappropriate. Trials of inhibiting endogenous NO synthesis with
NOS-inhibitors in critically ill patients with sepsis have been reported although, disappointingly, did not improve
outcome; indeed, the non-specific NOS-inhibitor, NG-methyl-L-arginine hydrochloride (L-NMMA, 546C88), was
associated with increased death.168 It is not clear why inhibiting NO synthesis was ineffective but non-selective NOS
inhibitors were used meaning that both toxic (iNOS) and beneficial (eNOS) sources of NO were inhibited; pharmaco-
logically, such inhibitors will have reduced cardiac output, organ perfusion and tissue oxygenation. In the absence of
licensed selective iNOS inhibitors, perhaps the analogous approach used in the management of hyperthyroidism using
block (with carbimazole) and replace (thyroxine) might be effective, i.e. block NOS activity and replace with a low dose
of a NO donor. That excess NO is dangerous does not mean that pharmacological doses of NO cannot be effective
(Figure 1, Tables 6, 11) since all effective interventions in medicine have an inverted “U” dose response.
Some infections have opposing in vitro and in vivo responses to NO. For example activated macrophage-derived NO or
NO donors such as SNAP reduced Trypanosoma brucei proliferation in vitro169,170 whereas endogenous iNOS-derived
NO suppressed protozoa-antigen specific T-cell proliferative responses and so worsened infection, at least in infected
mice.170 Intracellular protozoal infections are unlikely to be affected in this manner since macrophage-derived NOwould






[NO] pM nM µM
Notes 1 2 3 4
Figure 1. Schematic of concentration response curve for antimicrobial effects of nitric oxide.
1. Reduced eNOS-derived NO related to dietary insufficiency, older age, vascular disease
2. Normal eNOS-derived vascular NO
3. iNOS-derived NO or low/moderate dose exogenous NO source
4. iNOS-derived NO in septic shock or high dose exogenous NO source
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Other infections do not appear, at least in vitro, to induce iNOS. For example,Cryptococcus neoformans failed to induce
NOS in primed macrophages,172 apparently due to a lack of TNF-α secretion, probably because the polysaccharide
capsule masked the signal for TNF-α secretion. Interestingly, non-encapsulated mutants of C. neoformans did induce
endogenous NOS.
High levels of iNOS activation were antimicrobial in studies of malaria. Based on monocyte-derived mRNA levels in
circulating blood, uncomplicated malaria was associated with increased levels of iNOS activation in contrast to patients
with severe malaria who had lower levels.173
Table 10. Future research questions relating to nitric oxide therapy for microbes.
Question Microbe In vitro In vivo Clinical
trials



















What is the effect of timing on outcome in
prevention or treatment ofmild and severe disease?
Any
Could NO be used as a non-specific adjuvant to
antimicrobial therapy (where septic shock is absent)?
Any + +
Is the strategy of block (NOS inhibitor) and replace




Do NO sources, e.g. dietary nitrate or NO donors,
prevent/treat/improve outcome after COVID-19?
SARS-CoV-2 +
Do NO sources, e.g. dietary nitrate or NO donors,
prevent and treat outcome after endemic ‘flu?
SARS-CoV-2 +
Do combined NO and PG sources have agonistic
antimicrobial effects?
Any + + +






Do NO sources reduce chronic symptoms and
improve quality of life after infection?
Lyme disease +
NO: nitric oxide; PG: prostaglandin.
Table 11. Balance between potential beneficial and hazardous effects of NO sources in preventing and
treating infections.
Benefit Ineffective/Hazard
In vitro Considerable static/cidal
data
Limited neutral/negative data suggesting that there may be
publication bias
In vivo Some static/cidal data
Clinical Some positive phase II
trials
Concentration Moderate Low or very high (as in septic shock although NOS inhibitors
ineffective)
Microbial resistance to NO, e.g. synthesis of NO to resist oxidative
stress
Organic nitrates generate reactive NO species
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Epidemics and pandemics
Over recorded history, most epidemics and pandemics have resulted from viral infections including Ebola (viral
haemorrhagic fever), influenza (H1N1, H2N2, H3N2, H3N8), HIV-1 (AIDS), polio (poliomyelitis), smallpox, yellow
fever, zika or corona (OC43, MERS-CoV, SARS-CoV-1/2) viruses. Bacterial pandemics have resulted from Vibrio
cholerae (cholera), S. enterica (typhoid fever) and Yersinia pestis (plague). Studies in vitro have reported findings
suggesting that NO can reduce infection for some of these pathogens (Tables 2, 3) but information appears to be lacking
for smallpox, yellow fever, zika and cholera (Table 10).
With multiple pandemics over the last 100 years, it is only inevitable that further ones will occur and some, like COVID-
19, will comprise a “global catastrophic biological risk”.174 Global pandemics will most likely be caused by a respiratory-
spread virus that crosses over from animals such that humans have no inherent immunity to it. Likely candidates include
orthomyxoviruses (especially influenza A viruses such as H7N9), paramyxoviruses (e.g. measles, mumps, croup),
pneumovirus (e.g. human metapneumovirus), coronaviruses and picornaviruses (especially rhinoviruses and enterovi-
ruses). All of these have had strains that have crossed from animals to humans. This emphasis on RNA viruses is because
DNA viruses tend to have lower mutation rates and, therefore, evolvemore slowly and are less likely to escape the human
immune system within the first rounds of infection. Nevertheless, DNA viruses, such as pox or herpes viruses from great
apes or monkeys, do have the potential to jump species. Non-viral causes of pandemics are less likely since most bacteria
will be treatable with broad-spectrum antibacterial agents, most fungi are thermally restricted, and prions would require
massive food contamination (and only spread slowly).174 Protozoa are usually thermally restricted although global
warming may allow malaria to spread more widely in temperate zones.
Unfortunately, pandemics/epidemics may co-exist as seen with SARS-CoV-2 and dengue in Brazil,175 and both with
S. enterica in Pakistan;176,177 in part, this reflects increasing travel with aircraft providing a portal for numerous
microbes.178 Of theoretical concern was the potential for COVID-19 and epidemic influenza to co-exist during winter
in the Northern hemisphere, this possibly leading to a dramatic increase in deaths.179 Nevertheless, ‘flu rates were very
low in both southern and northern hemisphere 2020 winters, presumably due to hands, face, space, mask and fresh air
measures. All-in-all, the absence of a true broad-spectrum of antiviral agents is a major concern180 and a potential agent
such as NO with antimicrobial effects that extend beyond viruses would be most welcome.
Implications for SARS-CoV-2 and COVID-19
One possible explanation for the observation that COVID-19 outcomes are worse in older people, males, black or Asian
ethnicity, and those with co-morbidities such as diabetes, hypertension, stroke and chronic lung disease,181 is that these
groups have lower vascular NO activity4,5,9 and so mount a sub-optimal host response against infection. Increasing NO
availability is therefore a potential therapeutic strategy. Several NO sources have potential relevance to preventing and
treating COVID-19. L-arginine, sodium nitrite, GTN, SNP, NO and dipyridamole each have clinical antimicrobial
activity and can be administered, variously, orally, intravenously or as NO gas in the intensive care unit. Transdermal
GTN, and oral ISMN, dipyridamole and sildenafil may be administered in the community or hospital. Of these, NO gas,
dipyridamole and sildenafil are already being tested for preventing or treating COVID-19 (Table 9). It remains to be
determined if increasing dietary nitrate may be a cost effective and safe intervention of widespread health relevance for
the prevention of COVID-19 and, indeed, other emerging, pandemic, epidemic or endemic infections. Recent trial
evidence provides indirect supporting evidence for the potential anti-SARS-CoV-2 effect of NO. First, dexamethasone
and tocilizumab reduced death in patients in intensive care units,182,183 and these agents and NO share anti-inflammatory
effects. And second, interferon-ß reduced the need for intensive care in COVID-19 patients;184 type I interferons increase
iNOS activity and so have antimicrobial effects, as seen with L. major and Burkholderia pseudomallei.185,186
Discussion and conclusions
Nitric oxide is a fundamental molecule with wide-ranging and potent vascular, anti-platelet, anti-inflammatory and
tumoricidal effects. Further, there is a large volume of literature spanning the last 30+ years demonstrating that NO also
has potent in vitro antimicrobial effects on a wide variety of viruses, bacteria, protozoa, fungi and yeasts; these are
supported by amodest number of in vivo studies. Further, several positive clinical phase II trials of NO have been reported
in viral, bacterial, protozoa and fungal infections, these relating particularly to skin and respiratory infections admin-
istered by cream and gas respectively. Although not from randomised trials, there is also evidence that dietary nitrate
modifies the oral biome and so reduces dental caries.
However, these results cannot be considered persuasive on their own. First, few neutral or negative studies have been
reported suggesting that there may be a risk of publication bias. Second, conflicting data in some dual-protocol studies
with positive in vitro and neutral/negative in vivo data suggest that although NO is antimicrobial per se, the local tissue
environment may overcome or reverse this effect. Third, organic nitrates can suffer from tolerance and may lead to the
generation of reactive NO species such as peroxynitrite and S-nitrosothiols which might exacerbate rather than attenuate
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infection. Fourth, resistancemay develop although this seems unlikely to be a generic issue, not least becauseNO levels can
change, and be changed, much faster than any microbe can raise defensive mechanisms. Fifth, somemicrobes can produce
their own NO and use this to resist the oxidative stress induced by external NO and its derivatives. Sixth, excess NO
production is associated with the development of septic shock which might suggest that any NO is ineffective. Potentially,
unsuccessful trials of non-selectiveNOS-inhibitors in severe sepsismay have confused the issue, perhaps by suggesting that
treatment with NO is not important in infection. Seventh, positive clinical studies have been performed in environments
where very high local concentrations of NO can be achieved and without the risk of reactive responses, in particular on the
surface of tissues such as creamon the skin, dietary nitrate in themouth, nitrite in the stomach,NOgas in the lungs and nitrite
in the bladder; whether NO is effective as an antimicrobial within tissues and the vascular tree remains to be determined.
There are many sources of NO suitable for studying the prevention and treatment of milder infections in the community
and hospital (e.g. topical sodium nitrite, oral NO donors such as ISMN, or oral PDE5 inhibitors such as dipyridamole or
sildenafil), and treatment of serious infections in hospital (e.g. intravenous L-arginine, sodium nitrite or NO donors such
as GTN or SNP, of NO gas). NO may also be delivered via a high nitrate diet, thus offering a widely available and
inexpensive public health approach to potentially reducing and attenuating the severity of infections worldwide. This
approach has the added advantage that such diets are already known to reduce vascular disease and some cancers, and
possibly other inflammatory diseases and dementia.
In summary, the wealth of in vitro data suggest that NO has generic antimicrobial effects. However, some data suggest
that NOmay be ineffective or even hazardous and these reinforce our view for the need for large scale clinical trials of NO
donors in the community and hospitals to prevent and treat infections. Although such studies need to focus urgently on the
COVID-19 pandemic (especially with the lack of broad spectrum antiviral agents180), other pathogens also need to be
targeted. However, patients with established septic shock should not be administered NO donors to avoid exacerbating
vascular collapse. One utopian vision would be demonstration that high dietary nitrate intake produces pre- or post-
exposure prophylaxis against infections and their severity in the community whilst NO donors are effective antimicrobial
treatments for use by general practitioners and in hospitals.
Data availability
No data are associated with this article.
References
1. Palmer RMJ, Ashton DS, Moncada S: Vascular endothelial cells
synthesise nitric oxide from L-arginine. Nature. 1988; 333(6174):
664–6.
PubMed Abstract|Publisher Full Text
2. Bath PMW, Hassall DG, Gladwin A-M, et al. : Nitric oxide and
prostacyclin. Divergence of inhibitory effects on monocyte
chemotaxis and adhesion to endothelium in vitro. Arterioscler
Thromb. 1991; 11: 254–60.
PubMed Abstract|Publisher Full Text
3. Radomski MW, Palmer RMJ, Moncada S: Endogenous nitric oxide
inhibits human platelet adhesion to vascular endothelium.
Lancet. 1987; ii: 1057–8.
PubMed Abstract|Publisher Full Text
4. Ferlito S, Gallina M, Pitari GM, et al. : Nitric oxide plasma levels in
patients with chronic and acute cerebrovascular disorders.
Panminerva Med. 1998; 40: 51–4.
PubMed Abstract
5. Rashid P, Bath P: Plasma nitric oxide (nitrate) in stroke by type,
severity and outcome. Stroke. 2000; 31: 2835 (abstract).
PubMed Abstract|Publisher Full Text
6. Keller TT, Mairuhu AT, de Kruif MD, et al. : Infections and
endothelial cells. Cardiovasc Res. 2003; 60(1): 40–8.
PubMed Abstract|Publisher Full Text
7. Varga Z, Flammer AJ, Steiger P, et al.: Endothelial cell infection and
endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417–8.
PubMed Abstract|Publisher Full Text|Free Full Text
8. Ahmed S, Zimba O, Gasparyan AY: Thrombosis in Coronavirus
disease 2019 (COVID-19) through the prism of Virchow's triad.
Clin Rheumatol. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
9. GreenSJ:Covid-19accelerates endothelial dysfunctionandnitric
oxide deficiency. Microbes Infect. 2020; 22(4-5): 149–50.
PubMed Abstract|Publisher Full Text|Free Full Text
10. Griffith TM, Edwards DH, Lewis MJ, et al. : Evidence that cyclic
guanosine monophosphate (Cgmp) mediates endothelium-
dependent relaxation. Eur J Pharmacol. 1985; 112(2): 195–202.
PubMed Abstract|Publisher Full Text
11. RadomskiMW, Palmer RM,Moncada S: The role of nitric oxide and
cGMP in platelet adhesion to vascular endothelium. Biochem
Biophys Res Commun. 1987; 148(3): 1482–9.
PubMed Abstract|Publisher Full Text
12. Lowenstein CJ, Dinerman JL, Snyder SH:Nitric oxide: a physiologic
messenger. Ann Intern Med. 1994; 120(3): 227–37.
PubMed Abstract|Publisher Full Text
13. De Groote MA, Fang FC:NO inhibitions: antimicrobial properties
of nitric oxide. Clin Infect Dis. 1995; 21(Suppl 2): S162–5.
PubMed Abstract|Publisher Full Text
14. Fang FC: Perspectives series: host/pathogen interactions.
Mechanisms of nitric oxide-related antimicrobial activity. J Clin
Invest. 1997; 99(12): 2818–25.
PubMed Abstract|Publisher Full Text|Free Full Text
15. Vallance P, Charles I:Nitric oxide as an antimicrobial agent: does
NO always mean NO?. Gut. 1998; 42(3): 313–4.
PubMed Abstract|Publisher Full Text|Free Full Text
16. Reiss CS, Komatsu T: Does nitric oxide play a critical role in viral
infections? J Virol. 1998; 72(6): 4547–51.
PubMed Abstract|Publisher Full Text|Free Full Text
17. Burgner D, Rockett K, Kwiatkowski D: Nitric oxide and infectious
diseases. Arch Dis Child. 1999; 81(2): 185–8.
PubMed Abstract|Publisher Full Text|Free Full Text
18. Akaike T, Maeda H: Nitric oxide and virus infection. Immunology.
2000; 101(3): 300–8.
PubMed Abstract|Publisher Full Text|Free Full Text
19. Xu W, Zheng S, Dweik RA, et al. : Role of epithelial nitric oxide in
airway viral infection. Free Radic Biol Med. 2006; 41(1): 19–28.
PubMed Abstract|Publisher Full Text|Free Full Text
Page 26 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
20. Schairer DO, Chouake JS, Nosanchuk JD, et al. : The potential of
nitric oxide releasing therapies as antimicrobial agents.
Virulence. 2012; 3(3): 271–9.
PubMed Abstract|Publisher Full Text|Free Full Text
21. Stamler JS, Singel DJ, Loscalzo J: Biochemistry of nitric oxide and
its redox-activated froms. Science. 1992; 258(5090): 1898–902.
PubMed Abstract|Publisher Full Text
22. Koshland DJ: The molecule of the year. Science. 1992; 258(5090):
1861.
PubMed Abstract|Publisher Full Text
23. Howlett R: Nobel award stirs up debate on nitric oxide
breakthrough. Nature. 1998; 395(6703): 625–6.
PubMed Abstract|Publisher Full Text
24. Sohlman R: The Legacy of Alfred Nobel, The Story Behind The Nobel
Prizes. London: The Bodley Head; 1983.
25. Baltimore D: Expression of animal virus genomes. Bacteriol Rev.
1971; 35(3): 235–41.
PubMed Abstract|Publisher Full Text|Free Full Text
26. Lane TE, Paoletti AD, Buchmeier MJ: Disassociation between the
in vitro and in vivo effects of nitric oxide on a neurotropic
murine coronavirus. J Virol. 1997; 71(3): 2202–10.
PubMed Abstract|Publisher Full Text|Free Full Text
27. Jung K, Gurnani A, Renukaradhya GJ, et al. : Nitric oxide is elicited
and inhibits viral replication in pigs infected with porcine
respiratory coronavirus but not porcine reproductive and
respiratory syndrome virus. Vet Immunol Immunopathol. 2010;
136(3-4): 335–9.
PubMed Abstract|Publisher Full Text|Free Full Text
28. Keyaerts E, Vijgen L, Chen L, et al.: Inhibition of SARS-coronavirus
infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric
oxide donor compound. Int J Infect Dis. 2004; 8(4): 223–6.
PubMed Abstract|Publisher Full Text|Free Full Text
29. Akerström S, Mousavi-Jazi M, Klingström J, et al. : Nitric oxide
inhibits the replication cycle of severe acute respiratory
syndrome coronavirus. J Virol. 2005; 79(3): 1966–9.
PubMed Abstract|Publisher Full Text|Free Full Text
30. Goldshtein M, Lerner O, Kalaora R, et al.:Nitric oxide is a powerful
anti-coronavirus-inhaled agent that acts within hours. Chest.
2020; 158(4): 2446A–7A.
Publisher Full Text|Free Full Text
31. Chen L, Liu P, Gao H, et al. : Inhalation of nitric oxide in the
treatment of severe acute respiratory syndrome: a rescue trial
in Beijing. Clin Infect Dis. 2004; 39(10): 1531–5.
PubMed Abstract|Publisher Full Text|Free Full Text
32. Akaberi D, Krambrich J, Ling J, et al.:Mitigationof the replicationof
SARS-CoV-2 by nitric oxide in vitro. Redox Biol. 2020; 37: 101734.
PubMed Abstract|Publisher Full Text|Free Full Text
33. Liu X, Li Z, Liu S, et al. : Potential therapeutic effects of
dipyridamole in the severely ill patients with COVID-19. Acta
Pharm Sin B. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
34. Lisi F, Zelikin AN, Chandrawati R: Nitric Oxide to Fight Viral
Infections. Adv Sci (Weinh). 2021; 8(7): 2003895.
PubMed Abstract|Publisher Full Text|Free Full Text
35. Jiang Y, Fang L, Luo R, et al. : N-acetylpenicillamine inhibits the
replication of porcine reproductive and respiratory syndrome
virus in vitro. Vet Res Commun. 2010; 34(7): 607–17.
PubMed Abstract|Publisher Full Text|Free Full Text
36. Kaul P, Singh I, Turner RB: Effect of nitric oxide on rhinovirus
replication and virus-induced interleukin-8 elaboration.
Am J Respir Crit Care Med. 1999; 159(4 Pt 1): 1193–8.
PubMed Abstract|Publisher Full Text
37. Kono Y, Shibata H, Adachi K, et al. : Lactate-dependent killing of
Escherichia coli by nitrite plus hydrogen peroxide: a possible
role of nitrogen dioxide. Arch Biochem Biophys. 1994; 311(1): 153–9.
PubMed Abstract|Publisher Full Text
38. De Groote MA, Granger D, Xu Y, et al. : Genetic and redox
determinants of nitric oxide cytotoxicity in a Salmonella
typhimuriummodel. Proc Natl Acad Sci U S A. 1995; 92(14): 6399–3.
PubMed Abstract|Publisher Full Text|Free Full Text
39. WinkDA, KasprzakKS,MaragosCM, et al.:DNAdeaminatingability
and genotoxicity of nitric oxide and its progenitors. Science.
1991; 254(5034): 1001–3.
PubMed Abstract|Publisher Full Text
40. Fujikura Y, Kudlackova P, VokurkaM, et al.: Theeffect ofnitric oxide
on vaccinia virus-encoded ribonucleotide reductase.Nitric Oxide.
2009; 20(2): 114–21.
PubMed Abstract|Publisher Full Text
41. Granger DL, Lehninger AL: Sites of inhibition of mitochondrial
electron transport in macrophage-injured neoplastic cells. J Cell
Biol. 1982; 95(2 Pt 1): 527–35.
PubMed Abstract|Publisher Full Text|Free Full Text
42. Saura M, Zaragoza C, McMillan A, et al.: An antiviralmechanism of
nitric oxide: inhibition of a viral protease. Immunity. 1999; 10(1):
21–8.
PubMed Abstract|Publisher Full Text|Free Full Text
43. Mokry RL, Schumacher ML, Hogg N, et al. : Nitric Oxide
Circumvents Virus-Mediated Metabolic Regulation during
Human Cytomegalovirus Infection. mBio. 2020; 11(6).
PubMed Abstract|Publisher Full Text|Free Full Text
44. O’Leary V, Solberg M: Effect of sodium nitrite inhibition on
intracellular thiol groups and on the activity of certain
glycolytic enzymes in Clostridium perfringens. Appl Environ
Microbiol. 1976; 31(2): 208–12.
PubMed Abstract|Publisher Full Text|Free Full Text
45. Frawley ER, Karlinsey JE, Singhal A, et al.:Nitric Oxide Disrupts Zinc
Homeostasis in Salmonella enterica Serovar Typhimurium.
mBio. 2018; 9(4).
PubMed Abstract|Publisher Full Text|Free Full Text
46. Carpenter AW, Schoenfisch MH: Nitric oxide release:
part II. Therapeutic applications. Chem Soc Rev. 2012; 41(10):
3742–52.
PubMed Abstract|Publisher Full Text|Free Full Text
47. Mehta DR, Ashkar AA, Mossman KL: The nitric oxide pathway
provides innate antiviral protection in conjunction with the
type I interferon pathway in fibroblasts. PLoS One. 2012; 7(2):
e31688.
PubMed Abstract|Publisher Full Text|Free Full Text
48. Schön T, Elias D, Moges F, et al. : Arginine as an adjuvant to
chemotherapy improves clinical outcome in active
tuberculosis. Eur Respir J. 2003; 21(3): 483–8.
PubMed Abstract|Publisher Full Text
49. Henry BM, de Oliveira MHS, Benoit S, et al. : Hematologic,
biochemical and immune biomarker abnormalities associated
with severe illness and mortality in coronavirus disease 2019
(COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7):
1021–8.
PubMed Abstract|Publisher Full Text
50. Bikdeli B, Madhavan MV, Jimenez D, et al. : COVID-19
and Thrombotic or Thromboembolic Disease: Implications
for Prevention, Antithrombotic Therapy, and Follow-Up:
JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):
2950–73.
PubMed Abstract|Publisher Full Text|Free Full Text
51. Zamanian RT, Pollack CV, Gentile MA, et al. : Outpatient Inhaled
Nitric Oxide in a Patient with Vasoreactive Idiopathic
Pulmonary Arterial Hypertension and COVID-19 Infection.
Am J Respir Crit Care Med. 2020; 202(1): 130–2.
PubMed Abstract|Publisher Full Text|Free Full Text
52. Zumft WG: The biological role of nitric oxide in bacteria. Arch
Microbiol. 1993; 160(4): 253–64.
PubMed Abstract|Publisher Full Text
53. Chen Y, Rosazza JP: Purification and characterization of nitric
oxide synthase (NOSNoc) from a Nocardia species. J Bacteriol.
1995; 177(17): 5122–8.
PubMed Abstract|Publisher Full Text|Free Full Text
54. Sudhamsu J, Crane BR: Bacterial nitric oxide synthases: what are
they good for? Trends Microbiol. 2009; 17(5): 212–8.
PubMed Abstract|Publisher Full Text
55. Gusarov I, Shatalin K, Starodubtseva M, et al. : Endogenous nitric
oxide protects bacteria against a wide spectrum of antibiotics.
Science. 2009; 325(5946): 1380–4.
PubMed Abstract|Publisher Full Text|Free Full Text
56. Li DD, YangCC, Liu P, et al.: Effect ofNitricOxideon theAntifungal
Activity of Oxidative Stress and Azoles Against Candida
albicans. Indian J Microbiol. 2016; 56(2): 214–8.
PubMed Abstract|Publisher Full Text|Free Full Text
57. Chaudhari SS, KimM, Lei S, et al.:NitriteDerived fromEndogenous
Bacterial Nitric Oxide Synthase Activity Promotes Aerobic
Respiration. mBio. 2017; 8(4).
PubMed Abstract|Publisher Full Text|Free Full Text
58. RasG, Leroy S, TalonR:Nitric oxide synthase:What is its potential
role in the physiology of staphylococci in meat products? Int J
Food Microbiol. 2018; 282: 28–34.
PubMed Abstract|Publisher Full Text
59. Hendriks J, Oubrie A, Castresana J, et al.:Nitric oxide reductases in
bacteria. Biochim Biophys Acta. 2000; 1459(2-3): 266–73.
PubMed Abstract|Publisher Full Text
60. Poole RK: Flavohaemoglobin: the pre-eminent nitric oxide-
detoxifying machine of microorganisms. F1000Res. 2020; 9.
PubMed Abstract|Publisher Full Text|Free Full Text
61. Sebbane F, Lemaître N, Sturdevant DE, et al.: Adaptive response of
Yersinia pestis to extracellular effectors of innate immunity
during bubonic plague. Proc Natl Acad Sci U S A. 2006; 103(31):
Page 27 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
11766–71.
PubMed Abstract|Publisher Full Text|Free Full Text
62. Stern AM,Hay AJ, Liu Z, et al.: TheNorR regulon is critical for Vibrio
cholerae resistance to nitric oxide and sustained colonization of
the intestines. mBio. 2012; 3(2): e00013–12.
PubMed Abstract|Publisher Full Text|Free Full Text
63. Visca P, Fabozzi G,MilaniM, et al.:Nitric oxide andMycobacterium
leprae pathogenicity. IUBMB Life. 2002; 54(3): 95–9.
PubMed Abstract|Publisher Full Text
64. WorkmanAD,Carey RM,KohanskiMA, et al.:Relative susceptibility
of airway organisms to antimicrobial effects of nitric oxide. Int
Forum Allergy Rhinol. 2017; 7(8): 770–6.
PubMed Abstract|Publisher Full Text|Free Full Text
65. Privett BJ, Broadnax AD, Bauman SJ, et al.: Examination of bacterial
resistance to exogenous nitric oxide. Nitric Oxide. 2012; 26(3):
169–73.
PubMed Abstract|Publisher Full Text|Free Full Text
66. Baudouin SV, Bath P, Martin JF, et al. : L-arginine infusion has no
effect on systemic haemodynamics in normal volunteers, or
systemic and pulmonary haemodynamics in patients with
elevated pulmonary vascular resistance. Br J Clin Pharmacol.
1993; 36(1): 45–9.
PubMed Abstract|Publisher Full Text|Free Full Text
67. Ishikawa K, Kanamasa K, Ogawa I, et al. : Long-term nitrate
treatment increases cardiac events in patients with healed
myocardial infarction. Secondary Prevention Group. Jpn Circ J.
1996; 60(10): 779–88.
PubMed Abstract|Publisher Full Text
68. Redfield MM, Anstrom KJ, Levine JA, et al.: Isosorbide Mononitrate
in Heart Failure with Preserved Ejection Fraction. N Engl J Med.
2015; 373(24): 2314–24.
PubMed Abstract|Publisher Full Text|Free Full Text
69. Omar SA, Artime E, Webb AJ: A comparison of organic and
inorganic nitrates/nitrites. Nitric Oxide. 2012; 26(4): 229–40.
PubMed Abstract|Publisher Full Text
70. Daiber A, Münzel T: Organic Nitrate Therapy, Nitrate Tolerance,
and Nitrate-Induced Endothelial Dysfunction: Emphasis on
Redox Biology and Oxidative Stress. Antioxid Redox Signal. 2015;
23(11): 899–42.
PubMed Abstract|Publisher Full Text|Free Full Text
71. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic
mechanismof nitroglycerin bioactivation. Proc Natl Acad Sci U S A.
2002; 99(12): 8306–11.
PubMed Abstract|Publisher Full Text|Free Full Text
72. Bath P: The effect of nitric oxide-donating vasodilators on
monocyte chemotaxis and intracellular cGMP concentration
in vitro. Eur J Clin Pharmacol. 1993; 45(1): 53–8.
PubMed Abstract|Publisher Full Text
73. Mills CE, Khatri J, Maskell P, et al.: It is rocket science - why dietary
nitrate is hard to 'beet'! Part II: further mechanisms and
therapeutic potential of the nitrate-nitrite-NO pathway. Br J Clin
Pharmacol. 2017; 83(1): 140–51.
PubMed Abstract|Publisher Full Text|Free Full Text
74. Duncan C, Dougall H, Johnston P, et al. : Chemical generation of
nitric oxide in themouth from the enterosalivary circulation of
dietary nitrate. Nat Med. 1995; 1(6): 546–51.
PubMed Abstract|Publisher Full Text
75. Lundberg JO, Gladwin MT, Ahluwalia A, et al.:Nitrate and nitrite in
biology, nutrition and therapeutics. Nat Chem Biol. 2009; 5(12):
865–9.
PubMed Abstract|Publisher Full Text|Free Full Text
76. Doel JJ, Benjamin N, Hector MP, et al. : Evaluation of bacterial
nitrate reduction in the human oral cavity. Eur J Oral Sci. 2005;
113(1): 14–9.
PubMed Abstract|Publisher Full Text
77. Khatri J, Mills CE, Maskell P, et al.: It is rocket science - why dietary
nitrate is hard to 'beet'! Part I: twists and turns in the realization
of the nitrate-nitrite-NO pathway. Br J Clin Pharmacol. 2017; 83(1):
129–39.
PubMed Abstract|Publisher Full Text|Free Full Text
78. Koch CD, Gladwin MT, Freeman BA, et al. :
Enterosalivary nitrate metabolism and the microbiome:
Intersection of microbial metabolism, nitric oxide and diet
in cardiac and pulmonary vascular health. Free Radic Biol Med.
2017; 105: 48–67.
PubMed Abstract|Publisher Full Text|Free Full Text
79. Shimazu T, Kuriyama S, Hozawa A, et al. : Dietary patterns and
cardiovascular disease mortality in Japan: a prospective cohort
study. Int J Epidemiol. 2007; 36(3): 600–9.
PubMed Abstract|Publisher Full Text
80. Fung TT, Chiuve SE, McCullough ML, et al. : Adherence to a DASH-
style diet and risk of coronary heart disease and stroke in
women. Arch Intern Med. 2008; 168(7): 713–20.
PubMed Abstract|Publisher Full Text
81. Widmer RJ, Flammer AJ, Lerman LO, et al.: TheMediterranean diet,
its components, and cardiovascular disease. Am J Med. 2015;
128(3): 229–38.
PubMed Abstract|Publisher Full Text|Free Full Text
82. Estruch R, Ros E, Salas-Salvadó J, et al. : Primary Prevention of
Cardiovascular Disease with a Mediterranean Diet
Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med.
2018; 378(25): e34.
PubMed Abstract|Publisher Full Text
83. Bryan NS, Alexander DD, Coughlin JR, et al. : Ingested nitrate and
nitrite and stomach cancer risk: an updated review. Food Chem
Toxicol. 2012; 50(10): 3646–65.
PubMed Abstract|Publisher Full Text
84. Butler A:Nitrites and nitrates in the human diet: Carcinogens or
beneficial hypotensive agents? J Ethnopharmacol. 2015; 167:
105–7.
PubMed Abstract|Publisher Full Text
85. Zhang FX, Miao Y, Ruan JG, et al.: Association Between Nitrite and
Nitrate Intake and Risk of Gastric Cancer: A Systematic Review
and Meta-Analysis. Med Sci Monit. 2019; 25: 1788–99.
PubMed Abstract|Publisher Full Text|Free Full Text
86. Webb AJ, Patel N, Loukogeorgakis S, et al. : Acute blood pressure
lowering, vasoprotective, and antiplatelet properties of dietary
nitrate via bioconversion to nitrite. Hypertension. 2008; 51(3):
784–90.
PubMed Abstract|Publisher Full Text|Free Full Text
87. Kapil V, Milsom AB, Okorie M, et al. : Inorganic nitrate
supplementation lowers blood pressure in humans: role for
nitrite-derived NO. Hypertension. 2010; 56(2): 274–81.
PubMed Abstract|Publisher Full Text
88. Presley TD, Morgan AR, Bechtold E, et al. : Acute effect of a high
nitrate diet on brain perfusion in older adults. Nitric Oxide. 2011;
24(1): 34–42.
PubMed Abstract|Publisher Full Text|Free Full Text
89. Velmurugan S, Gan JM, Rathod KS, et al.: Dietary nitrate improves
vascular function in patients with hypercholesterolemia: a
randomized, double-blind, placebo-controlled study. Am J Clin
Nutr. 2016; 103(1): 25–38.
PubMed Abstract|Publisher Full Text|Free Full Text
90. Mills CE, Govoni V, Faconti L, et al. : Reducing Arterial Stiffness
Independently of Blood Pressure. The VaSera Trial. J Am Coll
Cardiol. 2017; 70(13): 1683–4.
PubMed Abstract|Publisher Full Text
91. Faconti L, Mills CE, Govoni V, et al. : Cardiac effects of 6 months'
dietary nitrate and spironolactone in patients with
hypertension andwith/at risk of type 2diabetes, in the factorial
design, double-blind, randomized controlled VaSera trial. Br J
Clin Pharmacol. 2019; 85(1): 169–80.
PubMed Abstract|Publisher Full Text|Free Full Text
92. Stanaway L, Rutherfurd-Markwick K, Page R, et al. : Performance
and Health Benefits of Dietary Nitrate Supplementation in
Older Adults: A Systematic Review. Nutrients. 2017; 9(11).
PubMed Abstract|Publisher Full Text|Free Full Text
93. Omar SA, Fok H, Tilgner KD, et al. : Paradoxical normoxia-
dependent selective actions of inorganic nitrite in human
muscular conduit arteries and related selective actions on
central blood pressures. Circulation. 2015; 131(4): 381–9;
discussion 9.
PubMed Abstract|Publisher Full Text
94. AshorAW, Lara J, SiervoM:Medium-termeffects ofdietarynitrate
supplementation on systolic and diastolic blood pressure in
adults: a systematic review andmeta-analysis. J Hypertens. 2017;
35(7): 1353–9.
PubMed Abstract|Publisher Full Text
95. Kapil V, Khambata RS, Robertson A, et al.: Dietary nitrate provides
sustained blood pressure lowering in hypertensive patients: a
randomized, phase 2, double-blind, placebo-controlled study.
Hypertension. 2015; 65(2): 320–7.
PubMed Abstract|Publisher Full Text|Free Full Text
96. Raubenheimer K, Bondonno C, Blekkenhorst L, et al. : Effects of
dietary nitrate on inflammation and immune function, and
implications for cardiovascular health. Nutr Rev. 2019.
PubMed Abstract|Publisher Full Text
97. Lundberg JO, Carlström M, Weitzberg E: Metabolic Effects of
Dietary Nitrate in Health and Disease. Cell Metab. 2018; 28(1):
9–22.
PubMed Abstract|Publisher Full Text
98. Bushnell C, Beavers D,Miller G, et al.:DietaryNitrate Supplements
and Ischemic Stroke Recovery: A Pilot Study. Stroke. 2017; 48:
AWP166.
Page 28 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
99. Ormesher L, Myers JE, Chmiel C, et al. : Effects of dietary nitrate
supplementation, from beetroot juice, on blood pressure in
hypertensive pregnant women: A randomised, double-blind,
placebo-controlled feasibility trial. Nitric Oxide. 2018; 80: 37–44.
PubMed Abstract|Publisher Full Text
100. Bailey SJ, Blackwell JR,Williams E, et al.: Twoweeks ofwatermelon
juice supplementation improves nitric oxide bioavailability
but not endurance exercise performance in humans. Nitric
Oxide. 2016; 59: 10–20.
PubMed Abstract|Publisher Full Text
101. McIlvenna LC, Monaghan C, Liddle L, et al.: Beetroot juice versus
chard gel: A pharmacokinetic and pharmacodynamic
comparisonofnitratebioavailability.Nitric Oxide.2017; 64: 61–7.
PubMed Abstract|Publisher Full Text
102. Isidori AM, Giannetta E, Pofi R, et al. : Targeting the NO-cGMP-
PDE5 pathway in COVID-19 infection. The DEDALO project.
Andrology. 2021; 9(1): 33–38.
PubMed Abstract|Publisher Full Text|Free Full Text
103. Mostafa T: Could Oral Phosphodiesterase 5 Inhibitors Have a
Potential Adjuvant Role in Combating COVID-19 Infection? Sex
Med Rev. 2021; 9(1): 15–22.
PubMed Abstract|Publisher Full Text|Free Full Text
104. Martel J, Ko YF, Young JD, et al. : Could nasal nitric oxide help to
mitigate the severity of COVID-19?Microbes Infect. 2020; 22(4-5):
168–71.
PubMed Abstract|Publisher Full Text|Free Full Text
105. Adler BL, Friedman AJ: Nitric oxide therapy for dermatologic
disease. Future Sci OA. 2015; 1(1): FSO37.
PubMed Abstract|Publisher Full Text|Free Full Text
106. Lautner G, Meyerhoff ME, Schwendeman SP: Biodegradable poly
(lactic-co-glycolic acid) microspheres loaded with S-nitroso-N-
acetyl-D-penicillamine for controlled nitric oxide delivery.
J Control Release. 2016; 225: 133–139.
PubMed Abstract|Publisher Full Text|Free Full Text
107. Pieretti JC, Rubilar O, Weller RB, et al. : Nitric oxide (NO) and
nanoparticles - Potential small tools for the war against
COVID-19 and other human coronavirus infections. Virus Res.
2021; 291: 198202.
PubMed Abstract|Publisher Full Text|Free Full Text
108. Contreras Lancheros CA, Pelegrino MT, Kian D, et al. : Selective
Antiprotozoal Activity of Nitric Oxide-releasing Chitosan
Nanoparticles Against Trypanosoma cruzi: Toxicity and
Mechanisms of Action. Curr Pharm Des. 2018; 24(7): 830–9.
PubMed Abstract|Publisher Full Text
109. Pelegrino MT, Pieretti JC, Nakazato G, et al. : Chitosan chemically
modified todelivernitric oxidewithhighantibacterial activity.
Nitric Oxide. 2021; 106: 24–34.
PubMed Abstract|Publisher Full Text
110. Sysel AM, Dunphy MJ, Bauer JA: Antimicrobial properties of
diethylamine NONOate, a nitric oxide donor, against
Escherichia coli: a pilot study. J Antibiot (Tokyo). 2021; 74(4): 260–5.
PubMed Abstract|Publisher Full Text|Free Full Text
111. GoudieMJ, Pant J, HandaH: Liquid-infused nitric oxide-releasing
(LINORel) silicone for decreased fouling, thrombosis, and
infection of medical devices. Sci Rep. 2017; 7(1): 13623.
PubMed Abstract|Publisher Full Text|Free Full Text
112. Pant J, Goudie MJ, Chaji SM, et al.:Nitric oxide releasing vascular
catheters for eradicating bacterial infection. J Biomed Mater Res
B Appl Biomater. 2018; 106(8): 2849–57.
PubMed Abstract|Publisher Full Text|Free Full Text
113. Duncan C, Li H, Dykhuizen R, et al. : Protection against oral and
gastrointestinal diseases: importance of dietary nitrate
intake, oral nitrate reduction and enterosalivary nitrate
circulation. Comp Biochem Physiol A Physiol. 1997; 118(4): 939–48.
PubMed Abstract|Publisher Full Text
114. Hohensinn B, Haselgrübler R, Müller U, et al.: Sustaining elevated
levels of nitrite in the oral cavity through consumption of
nitrate-rich beetroot juice in young healthy adults reduces
salivary pH. Nitric Oxide. 2016; 60: 10–15.
PubMed Abstract|Publisher Full Text
115. Vanhatalo A, Blackwell JR, L'Heureux JE, et al. : Nitrate-responsive
oral microbiome modulates nitric oxide homeostasis and
blood pressure in humans. Free Radic Biol Med. 2018; 124: 21–30.
PubMed Abstract|Publisher Full Text|Free Full Text
116. Burleigh MC, Liddle L, Monaghan C, et al. : Salivary nitrite
production is elevated in individuals with a higher abundance
of oral nitrate-reducing bacteria. Free Radic Biol Med. 2018; 120:
80–8.
PubMed Abstract|Publisher Full Text
117. Dougall HT, Smith L, Duncan C, et al. : The effect of
amoxycillin on salivary nitrite concentrations: an important
mechanismof adverse reactions? Br J Clin Pharmacol. 1995; 39(4):
460–2.
PubMed Abstract|Publisher Full Text|Free Full Text
118. Dykhuizen RS, Fraser A, McKenzie H, et al. : Helicobacter pylori is
killed by nitrite under acidic conditions. Gut. 1998; 42(3): 334–7.
PubMed Abstract|Publisher Full Text|Free Full Text
119. Halliday GM, Byrne SN: An unexpected role: UVA-induced
release of nitric oxide from skin may have unexpected health
benefits. J Invest Dermatol. 2014; 134(7): 1791–4.
PubMed Abstract|Publisher Full Text
120. Weller RB: SunlightHas Cardiovascular Benefits Independently
of Vitamin D. Blood Purif. 2016; 41(1-3): 130–4.
PubMed Abstract|Publisher Full Text
121. Weller R, Ormerod AD, Hobson RP, et al. : A randomized trial of
acidifiednitrite cream in the treatmentof tineapedis. J AmAcad
Dermatol. 1998; 38(4): 559–63.
PubMed Abstract|Publisher Full Text
122. Ormerod AD, White MI, Shah SA, et al. : Molluscum contagiosum
effectively treated with a topical acidified nitrite, nitric oxide
liberating cream. Br J Dermatol. 1999; 141(6): 1051–3.
PubMed Abstract|Publisher Full Text|Free Full Text
123. Davidson RN, Yardley V, Croft SL, et al. : A topical nitric oxide-
generating therapy for cutaneous leishmaniasis. Trans R Soc
Trop Med Hyg. 2000; 94(3): 319–22.
PubMed Abstract|Publisher Full Text
124. Phillips R, Adjei O, Lucas S, et al. : Pilot randomized double-blind
trial of treatment of Mycobacterium ulcerans disease (Buruli
ulcer)with topical nitrogen oxides. Antimicrob Agents Chemother.
2004; 48(8): 2866–70.
PubMed Abstract|Publisher Full Text|Free Full Text
125. Ormerod AD, Shah AA, Li H, et al. : An observational prospective
study of topical acidified nitrite for killingmethicillin-resistant
Staphylococcus aureus (MRSA) in contaminated wounds. BMC
Res Notes. 2011; 4: 458.
PubMed Abstract|Publisher Full Text|Free Full Text
126. Ormerod AD, van Voorst Vader PC,Majewski S, et al.: Evaluation of
the Efficacy, Safety, and Tolerability of 3 Dose Regimens of
Topical Sodium Nitrite With Citric Acid in Patients With
Anogenital Warts: A Randomized Clinical Trial. JAMA Dermatol.
2015; 151(8): 854–61.
PubMed Abstract|Publisher Full Text
127. Concannon M, Keogh L, Stephenson J, et al. : A randomized
comparative evaluation of clinical and home application to
investigate the effectiveness of silver nitrate (AgNO). Int J
Pharm Pract. 2017; 25(6): 421–8.
PubMed Abstract|Publisher Full Text
128. Runer T, Cervin A, Lindberg S, et al.:Nitric oxide is a regulator of
mucociliary activity in the upper respiratory tract. Otolaryngol
Head Neck Surg. 1998; 119(3): 278–87.
PubMed Abstract|Publisher Full Text
129. Ricciardolo FL: Multiple roles of nitric oxide in the airways.
Thorax. 2003; 58(2): 175–82.
PubMed Abstract|Publisher Full Text|Free Full Text
130. Zemke AC, Shiva S, Burns JL, et al. : Nitrite modulates bacterial
antibiotic susceptibility and biofilm formation in association
with airway epithelial cells. Free Radic Biol Med. 2014; 77: 307–16.
PubMed Abstract|Publisher Full Text|Free Full Text
131. Gómez FP, Amado VM, Roca J, et al. : Effect of nitric oxide
inhalation on gas exchange in acute severe pneumonia. Respir
Physiol Neurobiol. 2013; 187(2): 157–63.
PubMed Abstract|Publisher Full Text
132. Abou-Arab O, Huette P, Debouvries F, et al. : Inhaled nitric oxide
for critically ill Covid-19 patients: a prospective study. Crit Care.
2020; 24(1): 645.
PubMed Abstract|Publisher Full Text|Free Full Text
133. Lotz C, Muellenbach RM, Meybohm P, et al. : Effects of inhaled
nitric oxide in COVID-19-induced ARDS - Is it worthwhile? Acta
Anaesthesiol Scand. 2020.
PubMed Abstract|Publisher Full Text
134. Longobardo A, Montanari C, Shulman R, et al. : Inhaled nitric
oxide minimally improves oxygenation in COVID-19 related
acute respiratory distress syndrome. Br J Anaesth. 2021; 126(1):
e44–e6.
PubMed Abstract|Publisher Full Text|Free Full Text
135. Safaee Fakhr B, Wiegand SB, Pinciroli R, et al. : High
Concentrations ofNitric Oxide Inhalation Therapy in Pregnant
Patients With Severe Coronavirus Disease 2019 (COVID-19).
Obstet Gynecol. 2020; 136(6): 1109–13.
PubMed Abstract|Publisher Full Text|Free Full Text
136. Garfield B, McFadyen C, Briar C, et al. : Potential for personalised
application of inhaled nitric oxide in COVID-19 pneumonia. Br J
Anaesth. 2021; 126(2): e72–e5.
PubMed Abstract|Publisher Full Text|Free Full Text
Page 29 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
137. Carlsson S, Govoni M, Wiklund NP, et al. : In Vitro Evaluation of a
NewTreatment forUrinary Tract InfectionsCaused byNitrate-
Reducing Bacteria. Antimicrobial Agents and Chemotherapy. 2003;
47(12): 3713–8.
PubMed Abstract|Publisher Full Text|Free Full Text
138. Carlsson S,Weitzberg E, Wiklund P, et al.: Intravesical nitric oxide
delivery for prevention of catheter-associated urinary tract
infections. Antimicrob Agents Chemother. 2005; 49(6): 2352–5.
PubMed Abstract|Publisher Full Text|Free Full Text
139. Kishikawa H, Ebberyd A, Römling U, et al. : Control of pathogen
growth and biofilm formation using a urinary catheter that
releases antimicrobial nitrogenoxides. Free Radic BiolMed.2013;
65: 1257–64.
PubMed Abstract|Publisher Full Text
140. Jansson OT, Morcos E, Brundin L, et al.: The role of nitric oxide in
bacillus Calmette-Guérin mediated anti-tumour effects in
human bladder cancer. Br J Cancer. 1998; 78(5): 588–92.
PubMed Abstract|Publisher Full Text|Free Full Text
141. Morcos E, JanssonOT, Adolfsson J, et al.:Bacillus Calmette-Guerin
induces long-term local formationofnitric oxide in thebladder
via the induction of nitric oxide synthase activity in urothelial
cells. J Urol. 2001; 165(2): 678–82.
PubMed Abstract|Publisher Full Text
142. Curtis N, Sparrow A, Ghebreyesus TA, et al. : Considering BCG
vaccination to reduce the impact of COVID-19. Lancet. 2020;
395(10236): 1545–6.
PubMed Abstract|Publisher Full Text|Free Full Text
143. Mohapatra PR, Mishra B, Behera B: BCG vaccination induced
protection from COVID-19. Indian J Tuberc. 2020; In press.
PubMed Abstract|Publisher Full Text|Free Full Text
144. de Chaisemartin C, de Chaisemartin L:BCG vaccination in infancy
does not protect against COVID-19: Evidence from a natural
experiment in Sweden. Clin Infect Dis. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
145. Kevil CG, Kolluru GK, Pattillo CB, et al. : Inorganic nitrite therapy:
historical perspective and future directions. Free Radic Biol Med.
2011; 51(3): 576–93.
PubMed Abstract|Publisher Full Text|Free Full Text
146. Ras G, Bailly X, Chacornac JP, et al. : Contribution of nitric oxide
synthase from coagulase-negative staphylococci to the
development of red myoglobin derivatives. Int J Food Microbiol.
2018; 266: 310–6.
PubMed Abstract|Publisher Full Text
147. Rosenblatt J, Reitzel R, Dvorak T, et al. : Glyceryl trinitrate
complements citrate and ethanol in a novel antimicrobial
catheter lock solution to eradicate biofilm organisms.
Antimicrob Agents Chemother. 2013; 57(8): 3555–60.
PubMed Abstract|Publisher Full Text|Free Full Text
148. Hasan S, Albayaty YNS, Thierry B, et al.:Mechanistic studies of the
antibiofilm activity and synergy with antibiotics of isosorbide
mononitrate. Eur J Pharm Sci. 2018; 115: 50–6.
PubMed Abstract|Publisher Full Text
149. Aveyard J, Deller RC, Lace R, et al. : Antimicrobial Nitric Oxide
Releasing Contact Lens Gels for the Treatment of Microbial
Keratitis. ACS Appl Mater Interfaces. 2019; 11(41): 37491–501.
PubMed Abstract|Publisher Full Text
150. RIGHT-2 Investigators: Prehospital transdermal glyceryl
trinitrate in patients with ultra-acute presumed stroke
(RIGHT-2): an ambulance-based, randomised, sham-
controlled, blinded, phase 3 trial. Lancet. 2019; 393(10175):
1009–20.
Publisher Full Text
151. D'Onofrio C, Amici C, Puglianiello A, et al.: Comparative anti-viral
andanti-proliferative activity of PGA1andPGJ2 againstHTLV-I-
infected MT-2 cells. Int J Cancer. 1992; 51(3): 481–8.
PubMed Abstract|Publisher Full Text
152. Zardi EM, Vespasiani Gentilucci U, Picardi A, et al. : Iloprost: an
adjunctive approach to chronic viral hepatitis treatment. Med
Hypotheses. 2005; 64(1): 46–52.
PubMed Abstract|Publisher Full Text
153. Whitney JB, Asmal M, Geiben-Lynn R: Serpin induced antiviral
activity of prostaglandin synthetase-2 against HIV-1
replication. PLoS One. 2011; 6(4): e18589.
PubMed Abstract|Publisher Full Text|Free Full Text
154. Rezaee F, Harford TJ, Linfield DT, et al. : cAMP-dependent
activation of protein kinase A attenuates respiratory syncytial
virus-induced humanairway epithelial barrier disruption. PLoS
One. 2017; 12(7): e0181876.
PubMed Abstract|Publisher Full Text|Free Full Text
155. Das UN: Can Bioactive Lipids Inactivate Coronavirus (COVID-
19)? Arch Med Res. 2020; 51(3): 282–6.
PubMed Abstract|Publisher Full Text|Free Full Text
156. Blair GW, Appleton JP, Flaherty K, et al. : Tolerability, safety and
intermediary pharmacological effects of cilostazol and
isosorbide mononitrate, alone and combined, in patients with
lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1)
trial, a randomised clinical trial. EClinicalMedicine. 2019; 11:
34–43.
PubMed Abstract|Publisher Full Text|Free Full Text
157. Savy M, Edmond K, Fine PE, et al. : Landscape analysis of
interactions between nutrition and vaccine responses in
children. J Nutr. 2009; 139(11): 2154S–218S.
PubMed Abstract|Publisher Full Text
158. HoangT, Agger EM,Cassidy JP, et al.:Proteinenergymalnutrition
during vaccination has limited influence on vaccine efficacy
but abolishes immunity if administered during
Mycobacterium tuberculosis infection. Infect Immun. 2015;
83(5): 2118–26.
PubMed Abstract|Publisher Full Text|Free Full Text
159. Moldofsky H, Patcai J: Chronic widespread musculoskeletal
pain, fatigue, depression and disordered sleep in chronic post-
SARS syndrome; a case-controlled study. BMC Neurol. 2011; 11:
37.
PubMed Abstract|Publisher Full Text|Free Full Text
160. Rasa S,Nora-Krukle Z,HenningN, et al.:Chronic viral infections in
myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS). J Transl Med. 2018; 16(1): 268.
PubMed Abstract|Publisher Full Text|Free Full Text
161. Wilson C: Concern coronavirus may trigger post-viral fatigue
syndromes. New Sci. 2020; 246(3278): 10–11.
PubMed Abstract|Publisher Full Text|Free Full Text
162. Schmidt S, Gocheva V, Zumbrunn T, et al. : Treatment with
L-citrulline in patients with post-polio syndrome: study
protocol for a single-center, randomised, placebo-controlled,
double-blind trial. Trials. 2017; 18(1): 116.
PubMed Abstract|Publisher Full Text|Free Full Text
163. Chousterman BG, Swirski FK, Weber GF: Cytokine storm and
sepsis disease pathogenesis. Semin Immunopathol. 2017; 39(5):
517–28.
PubMed Abstract|Publisher Full Text
164. Torre D, Pugliese A, Speranza F: Role of nitric oxide in HIV-1
infection: friend or foe? Lancet Infect Dis. 2002; 2(5): 273–80.
PubMed Abstract|Publisher Full Text
165. Lin GL, McGinley JP, Drysdale SB, et al. : Epidemiology and
Immune Pathogenesis of Viral Sepsis. Front Immunol. 2018; 9:
2147.
PubMed Abstract|Publisher Full Text|Free Full Text
166. Delaloye J, CalandraT: Invasive candidiasis asa causeof sepsis in
the critically ill patient. Virulence. 2014; 5(1): 161–9.
PubMed Abstract|Publisher Full Text|Free Full Text
167. Hübner MP, Layland LE, Hoerauf A: Helminths and their
implication in sepsis - a new branch of their
immunomodulatory behaviour? Pathog Dis. 2013; 69(2): 127–41.
PubMed Abstract|Publisher Full Text|Free Full Text
168. López A, Lorente JA, Steingrub J, et al. : Multiple-center,
randomized, placebo-controlled, double-blind study of the
nitric oxide synthase inhibitor 546C88: effect on survival in
patients with septic shock. Crit Care Med. 2004; 32(1): 21–30.
PubMed Abstract|Publisher Full Text
169. Vincendeau P,Daulouède S, Veyret B, et al.:Nitric oxide-mediated
cytostatic activity on Trypanosoma brucei gambiense and
Trypanosoma brucei brucei. Exp Parasitol. 1992; 75(3): 353–60.
PubMed Abstract|Publisher Full Text
170. Sternberg J, Mabbott N, Sutherland I, et al. : Inhibition of nitric
oxide synthesis leads to reduced parasitemia in murine
Trypanosomabrucei infection. Infect Immun. 1994; 62(5): 2135–7.
PubMed Abstract|Publisher Full Text|Free Full Text
171. Green SJ, Scheller LF, Marletta MA, et al. : Nitric oxide: cytokine-
regulation of nitric oxide in host resistance to intracellular
pathogens. Immunol Lett. 1994; 43(1-2): 87–94.
PubMed Abstract|Publisher Full Text
172. Naslund PK, Miller WC, Granger DL: Cryptococcus neoformans
fails to induce nitric oxide synthase in primed murine
macrophage-like cells. Infect Immun. 1995; 63(4): 1298–304.
PubMed Abstract|Publisher Full Text|Free Full Text
173. Chiwakata CB, Hemmer CJ, Dietrich M: High levels of inducible
nitric oxide synthase mRNA are associated with increased
monocyte counts in blood and have a beneficial role in
Plasmodium falciparum malaria. Infect Immun. 2000; 68(1):
394–9.
PubMed Abstract|Publisher Full Text|Free Full Text
174. Adalja AA, WatsonM, Toner ES, et al.: Characteristics ofMicrobes
Most Likely to Cause Pandemics and Global Catastrophes. Curr
Top Microbiol Immunol. 2019; 424: 1–20.
PubMed Abstract|Publisher Full Text|Free Full Text
Page 30 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
175. Lorenz C, Azevedo TS, Chiaravalloti-Neto F: COVID-19 and dengue
fever: A dangerous combination for the health system in
Brazil. Travel Med Infect Dis. 2020; 35: 101659.
PubMed Abstract|Publisher Full Text|Free Full Text
176. Haqqi A, Khurram M, Din MSU, et al. : COVID-19 and Salmonella
Typhi co-epidemics inPakistan: A real problem. J Med Virol. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
177. Haqqi A, Awan UA, Ali M, et al. : COVID-19 and dengue virus
coepidemics in Pakistan: A dangerous combination for an
overburdened healthcare system. J Med Virol. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
178. Wilson ME: What goes on board aircraft? Passengers include
Aedes, Anopheles, 2019-nCoV, dengue, Salmonella, Zika, et al.
Travel Med Infect Dis. 2020; 33: 101572.
PubMed Abstract|Publisher Full Text|Free Full Text
179. Academy Medical Sciences:Preparing for a challenging winter
2020/21. London: Academy Medical Sciences; 2020.
180. Adalja A, Inglesby T: Broad-SpectrumAntiviral Agents: A Crucial
Pandemic Tool. Expert Rev Anti Infect Ther. 2019; 17(7): 467–70.
PubMed Abstract|Publisher Full Text|Free Full Text
181. Galloway JB, Norton S, Barker RD, et al. : A clinical risk score to
identify patients with COVID-19 at high risk of critical care
admission or death: An observational cohort study. J Infect.
2020.
PubMed Abstract|Publisher Full Text|Free Full Text
182. Horby P, Lim WS, Emberson JR, et al. : Dexamethasone in
HospitalizedPatientswith Covid-19 - PreliminaryReport.NEngl
J Med. 2020.
PubMed Abstract|Publisher Full Text|Free Full Text
183. The REMAP-CAP Investigators: Interleukin-6 Receptor
Antagonists in Critically Ill Patients with Covid-19 –
Preliminary report. medRxiv. 2021.
PubMed Abstract|Publisher Full Text|Free Full Text
184. RahmaniH, Davoudi-Monfared E, Nourian A, et al.: Interferon β-1b
in treatmentof severeCOVID-19: A randomized clinical trial. Int
Immunopharmacol. 2020; 88: 106903.
PubMed Abstract|Publisher Full Text|Free Full Text
185. Mattner J, Schindler H, Diefenbach A, et al. : Regulation of type
2 nitric oxide synthase by type 1 interferons in macrophages
infected with Leishmania major. Eur J Immunol. 2000; 30(8):
2257–67.
PubMed Abstract|Publisher Full Text
186. Utaisincharoen P, Anuntagool N, Limposuwan K, et al. :
Involvement of beta interferon in enhancing inducible nitric
oxide synthase production and antimicrobial activity of
Burkholderia pseudomallei-infected macrophages. Infect
Immun. 2003; 71(6): 3053–7.
PubMed Abstract|Publisher Full Text|Free Full Text
187. Floyd CN, Shahed F, Ukah F, et al. : Acute Blood Pressure-
Lowering Effects of Nitrogen Dioxide Exposure From
Domestic Gas Cooking Via Elevation of Plasma Nitrite
Concentration in Healthy Individuals. Circ Res. 2020; 127(6):
847–8.
PubMed Abstract|Publisher Full Text|Free Full Text
188. Karupiah G, Xie QW, Buller RM, et al. : Inhibition of viral
replication by interferon-gamma-induced nitric oxide
synthase. Science. 1993; 261(5127): 1445–8.
PubMed Abstract|Publisher Full Text
189. Mannick JB, Asano K, Izumi K, et al. : Nitric oxide produced by
human B lymphocytes inhibits apoptosis and Epstein-Barr
virus reactivation. Cell. 1994; 79(7): 1137–46.
PubMed Abstract|Publisher Full Text
190. CroenKD: Evidence for antiviral effect ofnitric oxide. Inhibition
of herpes simplex virus type 1 replication. J Clin Invest. 1993;
91(6): 2446–52.
PubMed Abstract|Publisher Full Text|Free Full Text
191. Harris N, Buller RM, Karupiah G: Gamma interferon-induced,
nitric oxide-mediated inhibition of vaccinia virus replication.
J Virol. 1995; 69(2): 910–5.
PubMed Abstract|Publisher Full Text|Free Full Text
192. Mĕlková Z, Esteban M: Inhibition of vaccinia virus DNA
replication by inducible expression of nitric oxide synthase.
J Immunol. (Baltimore, Md: 1950). 1995; 155(12): 5711–8.
PubMed Abstract
193. Liu C, Wen L, Xiao Q, et al. : Nitric oxide-generating compound
GSNO suppresses porcine circovirus type 2 infection in vitro
and in vivo. BMC Vet Res. 2017; 13(1): 59.
PubMed Abstract|Publisher Full Text|Free Full Text
194. Wei ZY, Wang XB, Ning XD, et al. : Nitric oxide inhibits the
replication cycle of porcine parvovirus in vitro. Arch Virol. 2009;
154(6): 999–1003.
PubMed Abstract|Publisher Full Text|Free Full Text
195. Pertile TL, Karaca K, Sharma JM, et al.: An antiviral effect of nitric
oxide: inhibition of reovirus replication. Avian Dis. 1996; 40(2):
342–8.
PubMed Abstract
196. Zaragoza C, Ocampo CJ, Saura M, et al. :Nitric oxide inhibition of
coxsackievirus replication in vitro. J Clin Invest. 1997; 100(7):
1760–7.
PubMed Abstract|Publisher Full Text|Free Full Text
197. Takhampunya R, Padmanabhan R, Ubol S: Antiviral action of
nitric oxide on dengue virus type 2 replication. J Gen Virol. 2006;
87(Pt 10): 3003–11.
PubMed Abstract|Publisher Full Text
198. Mannick JB, Stamler JS, Teng E, et al.:Nitric oxidemodulatesHIV-1
replication. J Acquir Immune Defic Syndr. 1999; 22(1): 1–9.
PubMed Abstract|Publisher Full Text
199. Lin YL, Huang YL, Ma SH, et al. : Inhibition of Japanese
encephalitis virus infection by nitric oxide: antiviral effect of
nitric oxide onRNAvirus replication. J Virol. 1997; 71(7): 5227–35.
PubMed Abstract|Publisher Full Text|Free Full Text
200. Fata-Hartley CL, Palmenberg AC: Dipyridamole reversibly
inhibits mengovirus RNA replication. J Virol. 2005; 79(17):
11062–70.
PubMed Abstract|Publisher Full Text|Free Full Text
201. Tucker PC, Griffin DE, Choi S, et al. : Inhibition of nitric oxide
synthesis increases mortality in Sindbis virus encephalitis.
J Virol. 1996; 70(6): 3972–7.
PubMed Abstract|Publisher Full Text|Free Full Text
202. Tonew E, Indulen MK, Dzeguze DR: Antiviral action of
dipyridamole and its derivatives against influenza virus A. Acta
Virol. 1982; 26(3): 125–9.
PubMed Abstract
203. Rimmelzwaan GF, Baars MM, de Lijster P, et al. Inhibition of
influenza virus replication by nitric oxide. J Virol. 1999; 73(10):
8880–3.
PubMed Abstract|Publisher Full Text|Free Full Text
204. Regev-Shoshani G, Vimalanathan S, McMullin B, et al. : Gaseous
nitric oxide reduces influenza infectivity in vitro. Nitric Oxide.
2013; 31: 48–53.
PubMed Abstract|Publisher Full Text|Free Full Text
205. Guidotti LG, McClary H, Loudis JM, et al. : Nitric oxide inhibits
hepatitis B virus replication in the livers of transgenic mice.
J Exp Med. 2000; 191(7): 1247–52.
PubMed Abstract|Publisher Full Text|Free Full Text
206. Klingström J, Akerström S, Hardestam J, et al. : Nitric oxide and
peroxynitrite have different antiviral effects against
hantavirus replication and free mature virions. Eur J Immunol.
2006; 36(10): 2649–57.
PubMed Abstract|Publisher Full Text|Free Full Text
207. Zheng S,DeBP, Choudhary S, et al.: Impaired innatehost defense
causes susceptibility to respiratory virus infections in cystic
fibrosis. Immunity. 2003; 18(5): 619–30.
PubMed Abstract|Publisher Full Text
208. Ubol S, Hiriote W, Anuntagool N, et al. : A radical form of nitric
oxide suppresses RNA synthesis of rabies virus. Virus Res. 2001;
81(1-2): 125–32.
PubMed Abstract|Publisher Full Text
209. Bi Z, Reiss CS: Inhibition of vesicular stomatitis virus infection
by nitric oxide. J Virol. 1995; 69(4): 2208–13.
PubMed Abstract|Publisher Full Text|Free Full Text
210. Akarid K, Sinet M, Desforges B, et al. : Inhibitory effect of nitric
oxide on the replication of a murine retrovirus in vitro and
in vivo. J Virol. 1995; 69(11): 7001–5.
PubMed Abstract|Publisher Full Text|Free Full Text
211. McMullin BB, Chittock DR, Roscoe DL, et al. : The antimicrobial
effect of nitric oxide on the bacteria that cause nosocomial
pneumonia in mechanically ventilated patients in the
intensive care unit. Respir Care. 2005; 50(11): 1451–6.
PubMed Abstract
212. Jiang X, Leonard B, Benson R, et al. : Macrophage control of
Brucella abortus: role of reactive oxygen intermediates and
nitric oxide. Cell Immunol. 1993; 151(2): 309–19.
PubMed Abstract|Publisher Full Text
213. Mayer J, Woods ML, Vavrin Z, et al. : Gamma interferon-induced
nitric oxide production reduces Chlamydia trachomatis
infectivity in McCoy cells. Infect Immun. 1993; 61(2): 491–7.
PubMed Abstract|Publisher Full Text|Free Full Text
214. Park J, Rikihisa Y: L-arginine-dependent killing of intracellular
Ehrlichia risticii by macrophages treated with gamma
interferon. Infect Immun. 1992; 60(9): 3504–8.
PubMed Abstract|Publisher Full Text|Free Full Text
215. Anthony LS, Morrissey PJ, Nano FE: Growth inhibition of
Francisella tularensis live vaccine strain by IFN-gamma-
Page 31 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
activated macrophages is mediated by reactive nitrogen
intermediates derived from L-arginine metabolism. J Immunol.
(Baltimore, Md: 1950). 1992; 148(6): 1829–34.
PubMed Abstract
216. Summersgill JT, Powell LA, Buster BL, et al. : Killing of Legionella
pneumophila by nitric oxide in gamma-interferon-activated
macrophages. J Leukoc Biol. 1992; 52(6): 625–9.
PubMed Abstract|Publisher Full Text
217. Feng HM, Walker DH: Interferon-gamma and tumor necrosis
factor-alpha exert their antirickettsial effect via induction of
synthesis of nitric oxide. Am J Pathol. 1993; 143(4): 1016–23.
PubMed Abstract|Free Full Text
218. de Giusti M, de Vito E: Inactivation of Yersinia enterocolitica by
nitrite and nitrate in food. Food Addit Contam. 1992; 9(5): 405–8.
PubMed Abstract|Publisher Full Text
219. Morris SL, Hansen JN: Inhibition of Bacillus cereus spore
outgrowth by covalent modification of a sulfhydryl group by
nitrosothiol and iodoacetate. J Bacteriol. 1981; 148(2): 465–71.
PubMed Abstract|Publisher Full Text|Free Full Text
220. Wakabayashi K, Nagai A, Sheikh AM, et al. : Transplantation of
human mesenchymal stem cells promotes functional
improvement and increased expression of neurotrophic
factors in a rat focal cerebral ischemia model. Journal of
neuroscience research. 2010; 88(5): 1017–25.
PubMed Abstract|Publisher Full Text
221. Jones M, Ganopolsky JG, Labbé A, et al. : Novel nitric oxide
producing probiotic wound healing patch: preparation and
in vivo analysis in a New Zealand white rabbit model of
ischaemic and infected wounds. Int Wound J. 2012; 9(3): 330–43.
PubMed Abstract|Publisher Full Text
222. Denis M: Tumor necrosis factor and granulocyte macrophage-
colony stimulating factor stimulate human macrophages to
restrict growth of virulent Mycobacterium avium and to kill
avirulentM. avium: killingeffectormechanismdependson the
generation of reactive nitrogen intermediates. J Leukoc Biol.
1991; 49(4): 380–7.
PubMed Abstract|Publisher Full Text
223. Adams LB, Franzblau SG, Vavrin Z, et al. : L-arginine-dependent
macrophage effector functions inhibit metabolic activity of
Mycobacterium leprae. J Immunol. (Baltimore, Md: 1950) 1991;
147(5): 1642–6.
PubMed Abstract
224. Phillips R, Kuijper S, Benjamin N, et al. : In vitro killing of
Mycobacterium ulcerans by acidified nitrite. Antimicrob Agents
Chemother. 2004; 48(8): 3130–2.
PubMed Abstract|Publisher Full Text|Free Full Text
225. Lin JY, Chadee K: Macrophage cytotoxicity against Entamoeba
histolytica trophozoites is mediated by nitric oxide from
L-arginine. J Immunol. (Baltimore, Md: 1950). 1992; 148(12):
3999–4005.
PubMed Abstract
226. Fischer-Stenger K, Marciano-Cabral F: The arginine-dependent
cytolytic mechanism plays a role in destruction of Naegleria
fowleri amoebae by activated macrophages. Infect Immun.
1992; 60(12): 5126–31.
PubMed Abstract|Publisher Full Text|Free Full Text
227. Haswell-ElkinsMR, Satarug S, TsudaM, et al.: Liver fluke infection
and cholangiocarcinoma: model of endogenous nitric oxide
and extragastric nitrosation in human carcinogenesis. Mutat
Res. 1994; 305(2): 241–52.
PubMed Abstract|Publisher Full Text
228. Orjuela-Sánchez P, Ong PK, Zanini GM, et al. : Transdermal
glyceryl trinitrate as an effective adjunctive treatment with
artemether for late-stage experimental cerebral malaria.
Antimicrob Agents Chemother. 2013; 57(11): 5462–71.
PubMed Abstract|Publisher Full Text|Free Full Text
229. James SL, Glaven J: Macrophage cytotoxicity against
schistosomula of Schistosoma mansoni involves arginine-
dependent production of reactive nitrogen intermediates.
J Immunol. (Baltimore, Md: 1950). 1989; 143(12): 4208–12.
PubMed Abstract
230. Shen J, Lai DH, Wilson RA, et al. : Nitric oxide blocks the
development of the human parasite. Proc Natl Acad Sci U S A.
2017; 114(38): 10214–9.
PubMed Abstract|Publisher Full Text|Free Full Text
231. Kawakami NY, Tomiotto-Pellissier F, Cataneo AH, et al. : Sodium
nitroprussidehas leishmanicidal activity independent of iNOS.
Rev Soc Bras Med Trop. 2016; 49(1): 68–73.
PubMed Abstract|Publisher Full Text
232. Adams LB, Hibbs JB, Taintor RR, et al. : Microbiostatic effect of
murine-activated macrophages for Toxoplasma gondii. Role
for synthesis of inorganic nitrogen oxides from L-arginine.
J Immunol. (Baltimore, Md: 1950) 1990; 144(7): 2725–9.
PubMed Abstract
233. Hayashi S, Chan CC, Gazzinelli RT, et al. : Protective role of nitric
oxide in ocular toxoplasmosis. Br J Ophthalmol. 1996; 80(7):
644–8.
PubMed Abstract|Publisher Full Text|Free Full Text
234. Gross NT, Nessa K, Camner P, et al.: Production of nitric oxide by
rat alveolar macrophages stimulated by Cryptococcus
neoformans or Aspergillus fumigatus. Med Mycol. 1999; 37(3):
151–7.
PubMed Abstract
235. Lane TE, Wu-Hsieh BA, Howard DH: Antihistoplasma effect of
activated mouse splenic macrophages involves production of
reactive nitrogen intermediates. Infect Immun. 1994; 62(5):
1940–5.
PubMed Abstract|Publisher Full Text|Free Full Text
236. Downing JF, Kachel DL, Pasula R, et al. : Gamma interferon
stimulates rat alveolar macrophages to kill Pneumocystis
carinii by L-arginine- and tumor necrosis factor-dependent
mechanisms. Infect Immun. 1999; 67(3): 1347–52.
PubMed Abstract|Publisher Full Text|Free Full Text
237. Cenci E, Romani L, Mencacci A, et al. : Interleukin-4
and interleukin-10 inhibit nitric oxide-dependent
macrophage killing of Candida albicans. Eur J Immunol. 1993;
23(5): 1034–8.
PubMed Abstract|Publisher Full Text
238. Alspaugh JA, Granger DL: Inhibition of Cryptococcus
neoformans replicationbynitrogenoxides supports the role of
these molecules as effectors of macrophage-mediated
cytostasis. Infect Immun. 1991; 59(7): 2291–6.
PubMed Abstract|Publisher Full Text|Free Full Text
239. Stasko N, McHale K, Hollenbach SJ, et al. : Nitric Oxide-Releasing
Macromolecule Exhibits Broad-Spectrum Antifungal Activity
and Utility as a Topical Treatment for Superficial Fungal
Infections. Antimicrob Agents Chemother 2018; 62(7).
PubMed Abstract|Publisher Full Text|Free Full Text
240. Hall CN, Garthwaite J: What is the real physiological NO
concentration in vivo? Nitric Oxide. 2009; 21(2): 92–103.
PubMed Abstract|Publisher Full Text|Free Full Text
241. Ohta K, Rosner G, Graf R: Nitric oxide generation from sodium
nitroprusside and hydroxylamine in brain. Neuroreport. 1997;
8(9-10): 2229–35.
PubMed Abstract|Publisher Full Text
242. Bátai I, Kerényi M, Tekeres M: The growth of bacteria in
intravenous glyceryl trinitrate and in sodium nitroprusside.
Anesth Analg. 1999; 89(6): 1570–2.
PubMed Abstract|Publisher Full Text
243. Barraud N, Storey MV, Moore ZP, et al. : Nitric oxide-mediated
dispersal in single- and multi-species biofilms of clinically and
industrially relevant microorganisms. Microb Biotechnol. 2009;
2(3): 370–8.
PubMed Abstract|Publisher Full Text|Free Full Text
244. Miller C, McMullin B, Ghaffari A, et al. : Gaseous nitric
oxide bactericidal activity retained during intermittent
high-dose short duration exposure. Nitric Oxide. 2009; 20(1):
16–23.
PubMed Abstract|Publisher Full Text
245. Jones ML, Ganopolsky JG, Labbé A, et al. : A novel nitric oxide
producing probiotic patch and its antimicrobial efficacy:
preparation and in vitro analysis. Appl Microbiol Biotechnol. 2010;
87(2): 509–16.
PubMed Abstract|Publisher Full Text
246. Tonew M, Tonew E, Mentel R: The antiviral activity of
dipyridamole. Acta Virol. 1977; 21(2): 146–50.
PubMed Abstract
247. Booth L, Roberts JL, Cash DR, et al. : GRP78/BiP/HSPA5/Dna K is a
universal therapeutic target for human disease. J Cell Physiol.
2015; 230(7): 1661–76.
PubMed Abstract|Publisher Full Text|Free Full Text
248. Roberts JL, Tavallai M, Nourbakhsh A, et al. : GRP78/Dna K Is a
Target for Nexavar/Stivarga/Votrient in the Treatment of
Human Malignancies, Viral Infections and Bacterial Diseases.
J Cell Physiol. 2015; 230(10): 2552–78.
PubMed Abstract|Publisher Full Text|Free Full Text
249. Hardwick JB, Tucker AT, Wilks M, et al. : A novel method for the
delivery of nitric oxide therapy to the skin of human subjects
using a semi-permeable membrane. Clin Sci (Lond). 2001; 100(4):
395–400.
PubMed Abstract
250. Riccio DA, Schoenfisch MH: Nitric oxide release: part
I.Macromolecular scaffolds. ChemSoc Rev. 2012; 41(10): 3731–41.
PubMed Abstract|Publisher Full Text|Free Full Text
Page 32 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
251. Jin H, Yang L, Ahonen MJR, et al. : Nitric Oxide-Releasing
Cyclodextrins. J Am Chem Soc. 2018; 140(43): 14178–84.
PubMed Abstract|Publisher Full Text|Free Full Text
252. Sadrearhami Z, Nguyen TK, Namivandi-Zangeneh R, et al.: Recent
advances in nitric oxide delivery for antimicrobial applications
using polymer-based systems. J Mater Chem B. 2018; 6(19):
2945–59.
PubMed Abstract|Publisher Full Text
253. Sharma K, Sengupta K, Chakrapani H: Nitroreductase-activated
nitric oxide (NO) prodrugs. Bioorg Med Chem Lett. 2013; 23(21):
5964–67.
PubMed Abstract|Publisher Full Text
254. Hibbard HAJ, Reynolds MM: Synthesis of novel nitroreductase
enzyme-activated nitric oxide prodrugs to site-specifically kill
bacteria. Bioorg Chem. 2019; 93: 103318.
PubMed Abstract|Publisher Full Text
255. Alvarez RA, Berra L, Gladwin MT: Home Nitric Oxide
Therapy for COVID-19. Am J Respir Crit Care Med. 2020; 202(1):
16–20.
PubMed Abstract|Publisher Full Text|Free Full Text
Page 33 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias•
You can publish traditional articles, null/negative results, case reports, data notes and more•
The peer review process is transparent and collaborative•
Your article is indexed in PubMed after passing peer review•
Dedicated customer support at every stage•
For pre-submission enquiries, contact research@f1000.com
Page 34 of 34
F1000Research 2021, 10:536 Last updated: 05 JUL 2021
